JPH02215778A - 3,4-dihydro-2h-benzopyrane derivative and medical use of the same compound - Google Patents
3,4-dihydro-2h-benzopyrane derivative and medical use of the same compoundInfo
- Publication number
- JPH02215778A JPH02215778A JP3570389A JP3570389A JPH02215778A JP H02215778 A JPH02215778 A JP H02215778A JP 3570389 A JP3570389 A JP 3570389A JP 3570389 A JP3570389 A JP 3570389A JP H02215778 A JPH02215778 A JP H02215778A
- Authority
- JP
- Japan
- Prior art keywords
- dihydro
- compound
- group
- tetramethyl
- formula
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 150000001875 compounds Chemical class 0.000 title claims abstract description 59
- VZWXIQHBIQLMPN-UHFFFAOYSA-N chromane Chemical class C1=CC=C2CCCOC2=C1 VZWXIQHBIQLMPN-UHFFFAOYSA-N 0.000 title claims description 26
- 125000000217 alkyl group Chemical group 0.000 claims abstract description 10
- 125000003118 aryl group Chemical group 0.000 claims abstract description 10
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims abstract description 6
- 201000010099 disease Diseases 0.000 claims abstract description 5
- 208000002193 Pain Diseases 0.000 claims abstract description 4
- 125000003710 aryl alkyl group Chemical group 0.000 claims abstract description 4
- 125000004076 pyridyl group Chemical group 0.000 claims abstract description 4
- 102000001381 Arachidonate 5-Lipoxygenase Human genes 0.000 claims description 13
- 108010093579 Arachidonate 5-lipoxygenase Proteins 0.000 claims description 13
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims description 12
- 239000000126 substance Substances 0.000 claims description 12
- 125000001424 substituent group Chemical group 0.000 claims description 12
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 8
- 230000003859 lipid peroxidation Effects 0.000 claims description 8
- NTYJJOPFIAHURM-UHFFFAOYSA-N Histamine Chemical compound NCCC1=CN=CN1 NTYJJOPFIAHURM-UHFFFAOYSA-N 0.000 claims description 6
- 239000008194 pharmaceutical composition Substances 0.000 claims description 6
- 208000026935 allergic disease Diseases 0.000 claims description 5
- 208000006673 asthma Diseases 0.000 claims description 4
- 239000000654 additive Substances 0.000 claims description 3
- 229960001340 histamine Drugs 0.000 claims description 3
- 201000004681 Psoriasis Diseases 0.000 claims description 2
- 208000007536 Thrombosis Diseases 0.000 claims description 2
- 230000000996 additive effect Effects 0.000 claims description 2
- 208000026106 cerebrovascular disease Diseases 0.000 claims description 2
- 208000026278 immune system disease Diseases 0.000 claims description 2
- 208000030603 inherited susceptibility to asthma Diseases 0.000 claims 1
- 208000031225 myocardial ischemia Diseases 0.000 claims 1
- 150000001732 carboxylic acid derivatives Chemical class 0.000 abstract description 16
- 150000001412 amines Chemical class 0.000 abstract description 11
- 230000000694 effects Effects 0.000 abstract description 11
- 239000002253 acid Substances 0.000 abstract description 8
- 239000003795 chemical substances by application Substances 0.000 abstract description 2
- 238000002360 preparation method Methods 0.000 abstract description 2
- DLFVBJFMPXGRIB-UHFFFAOYSA-N Acetamide Chemical compound CC(N)=O DLFVBJFMPXGRIB-UHFFFAOYSA-N 0.000 abstract 2
- 239000000463 material Substances 0.000 abstract 1
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 30
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 23
- 238000006243 chemical reaction Methods 0.000 description 23
- 239000000243 solution Substances 0.000 description 23
- 238000012360 testing method Methods 0.000 description 19
- 230000002401 inhibitory effect Effects 0.000 description 18
- 230000000704 physical effect Effects 0.000 description 18
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 16
- -1 p-methoxybenzyl group Chemical group 0.000 description 16
- 239000000047 product Substances 0.000 description 16
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 15
- 239000000203 mixture Substances 0.000 description 14
- 230000002829 reductive effect Effects 0.000 description 14
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 12
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 12
- 239000003814 drug Substances 0.000 description 11
- QTBSBXVTEAMEQO-UHFFFAOYSA-N acetic acid Substances CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 10
- 238000009835 boiling Methods 0.000 description 10
- 238000000034 method Methods 0.000 description 10
- FYSNRJHAOHDILO-UHFFFAOYSA-N thionyl chloride Chemical compound ClS(Cl)=O FYSNRJHAOHDILO-UHFFFAOYSA-N 0.000 description 10
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 9
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 9
- 239000011259 mixed solution Substances 0.000 description 9
- YZXBAPSDXZZRGB-DOFZRALJSA-N arachidonic acid Chemical compound CCCCC\C=C/C\C=C/C\C=C/C\C=C/CCCC(O)=O YZXBAPSDXZZRGB-DOFZRALJSA-N 0.000 description 8
- 235000019441 ethanol Nutrition 0.000 description 8
- GUGOEEXESWIERI-UHFFFAOYSA-N Terfenadine Chemical compound C1=CC(C(C)(C)C)=CC=C1C(O)CCCN1CCC(C(O)(C=2C=CC=CC=2)C=2C=CC=CC=2)CC1 GUGOEEXESWIERI-UHFFFAOYSA-N 0.000 description 7
- 230000000202 analgesic effect Effects 0.000 description 7
- 230000001387 anti-histamine Effects 0.000 description 7
- 239000000739 antihistaminic agent Substances 0.000 description 7
- 238000010992 reflux Methods 0.000 description 7
- 238000000926 separation method Methods 0.000 description 7
- 238000010898 silica gel chromatography Methods 0.000 description 7
- 239000002904 solvent Substances 0.000 description 7
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 6
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 6
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 6
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 6
- 150000001733 carboxylic acid esters Chemical class 0.000 description 6
- 239000012044 organic layer Substances 0.000 description 6
- 125000006239 protecting group Chemical group 0.000 description 6
- 238000001228 spectrum Methods 0.000 description 6
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 5
- 229940114079 arachidonic acid Drugs 0.000 description 5
- 238000007796 conventional method Methods 0.000 description 5
- 238000001816 cooling Methods 0.000 description 5
- 125000005843 halogen group Chemical group 0.000 description 5
- WSLDOOZREJYCGB-UHFFFAOYSA-N 1,2-Dichloroethane Chemical compound ClCCCl WSLDOOZREJYCGB-UHFFFAOYSA-N 0.000 description 4
- CUYKNJBYIJFRCU-UHFFFAOYSA-N 3-aminopyridine Chemical compound NC1=CC=CN=C1 CUYKNJBYIJFRCU-UHFFFAOYSA-N 0.000 description 4
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 4
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 4
- KYNSBQPICQTCGU-UHFFFAOYSA-N Benzopyrane Chemical compound C1=CC=C2C=CCOC2=C1 KYNSBQPICQTCGU-UHFFFAOYSA-N 0.000 description 4
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 4
- KDLHZDBZIXYQEI-UHFFFAOYSA-N Palladium Chemical compound [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 4
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 4
- 235000021342 arachidonic acid Nutrition 0.000 description 4
- 125000004432 carbon atom Chemical group C* 0.000 description 4
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 description 4
- 229940079593 drug Drugs 0.000 description 4
- 239000000543 intermediate Substances 0.000 description 4
- 150000002617 leukotrienes Chemical class 0.000 description 4
- OKKJLVBELUTLKV-UHFFFAOYSA-N methanol Substances OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 4
- 239000000546 pharmaceutical excipient Substances 0.000 description 4
- 239000011541 reaction mixture Substances 0.000 description 4
- 229920006395 saturated elastomer Polymers 0.000 description 4
- 239000011780 sodium chloride Substances 0.000 description 4
- 229940124597 therapeutic agent Drugs 0.000 description 4
- QAIPRVGONGVQAS-DUXPYHPUSA-N trans-caffeic acid Chemical compound OC(=O)\C=C\C1=CC=C(O)C(O)=C1 QAIPRVGONGVQAS-DUXPYHPUSA-N 0.000 description 4
- WZZBNLYBHUDSHF-DHLKQENFSA-N 1-[(3s,4s)-4-[8-(2-chloro-4-pyrimidin-2-yloxyphenyl)-7-fluoro-2-methylimidazo[4,5-c]quinolin-1-yl]-3-fluoropiperidin-1-yl]-2-hydroxyethanone Chemical compound CC1=NC2=CN=C3C=C(F)C(C=4C(=CC(OC=5N=CC=CN=5)=CC=4)Cl)=CC3=C2N1[C@H]1CCN(C(=O)CO)C[C@@H]1F WZZBNLYBHUDSHF-DHLKQENFSA-N 0.000 description 3
- KGIJOOYOSFUGPC-MSFIICATSA-N 5-Hydroxyeicosatetraenoic acid Chemical compound CCCCCC=CCC=CCC=C\C=C\[C@@H](O)CCCC(O)=O KGIJOOYOSFUGPC-MSFIICATSA-N 0.000 description 3
- KGIJOOYOSFUGPC-XRXZHELTSA-N 5-hydroxyeicosatetraenoic acid Natural products CCCCCC=CCC=CCC=C\C=C\C(O)CCCC(O)=O KGIJOOYOSFUGPC-XRXZHELTSA-N 0.000 description 3
- QOSSAOTZNIDXMA-UHFFFAOYSA-N Dicylcohexylcarbodiimide Chemical compound C1CCCCC1N=C=NC1CCCCC1 QOSSAOTZNIDXMA-UHFFFAOYSA-N 0.000 description 3
- KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 description 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 3
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 3
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 3
- LJOOWESTVASNOG-UFJKPHDISA-N [(1s,3r,4ar,7s,8s,8as)-3-hydroxy-8-[2-[(4r)-4-hydroxy-6-oxooxan-2-yl]ethyl]-7-methyl-1,2,3,4,4a,7,8,8a-octahydronaphthalen-1-yl] (2s)-2-methylbutanoate Chemical compound C([C@H]1[C@@H](C)C=C[C@H]2C[C@@H](O)C[C@@H]([C@H]12)OC(=O)[C@@H](C)CC)CC1C[C@@H](O)CC(=O)O1 LJOOWESTVASNOG-UFJKPHDISA-N 0.000 description 3
- PSLUFJFHTBIXMW-WYEYVKMPSA-N [(3r,4ar,5s,6s,6as,10s,10ar,10bs)-3-ethenyl-10,10b-dihydroxy-3,4a,7,7,10a-pentamethyl-1-oxo-6-(2-pyridin-2-ylethylcarbamoyloxy)-5,6,6a,8,9,10-hexahydro-2h-benzo[f]chromen-5-yl] acetate Chemical compound O([C@@H]1[C@@H]([C@]2(O[C@](C)(CC(=O)[C@]2(O)[C@@]2(C)[C@@H](O)CCC(C)(C)[C@@H]21)C=C)C)OC(=O)C)C(=O)NCCC1=CC=CC=N1 PSLUFJFHTBIXMW-WYEYVKMPSA-N 0.000 description 3
- 238000010640 amide synthesis reaction Methods 0.000 description 3
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 description 3
- 125000001309 chloro group Chemical group Cl* 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 238000001035 drying Methods 0.000 description 3
- 125000001153 fluoro group Chemical group F* 0.000 description 3
- 238000009472 formulation Methods 0.000 description 3
- 238000011534 incubation Methods 0.000 description 3
- 230000005764 inhibitory process Effects 0.000 description 3
- 208000023589 ischemic disease Diseases 0.000 description 3
- 238000004519 manufacturing process Methods 0.000 description 3
- 238000001819 mass spectrum Methods 0.000 description 3
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 3
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 3
- 239000008279 sol Substances 0.000 description 3
- 239000000600 sorbitol Substances 0.000 description 3
- 235000010356 sorbitol Nutrition 0.000 description 3
- 239000006228 supernatant Substances 0.000 description 3
- SZUVGFMDDVSKSI-WIFOCOSTSA-N (1s,2s,3s,5r)-1-(carboxymethyl)-3,5-bis[(4-phenoxyphenyl)methyl-propylcarbamoyl]cyclopentane-1,2-dicarboxylic acid Chemical compound O=C([C@@H]1[C@@H]([C@](CC(O)=O)([C@H](C(=O)N(CCC)CC=2C=CC(OC=3C=CC=CC=3)=CC=2)C1)C(O)=O)C(O)=O)N(CCC)CC(C=C1)=CC=C1OC1=CC=CC=C1 SZUVGFMDDVSKSI-WIFOCOSTSA-N 0.000 description 2
- GHYOCDFICYLMRF-UTIIJYGPSA-N (2S,3R)-N-[(2S)-3-(cyclopenten-1-yl)-1-[(2R)-2-methyloxiran-2-yl]-1-oxopropan-2-yl]-3-hydroxy-3-(4-methoxyphenyl)-2-[[(2S)-2-[(2-morpholin-4-ylacetyl)amino]propanoyl]amino]propanamide Chemical compound C1(=CCCC1)C[C@@H](C(=O)[C@@]1(OC1)C)NC([C@H]([C@@H](C1=CC=C(C=C1)OC)O)NC([C@H](C)NC(CN1CCOCC1)=O)=O)=O GHYOCDFICYLMRF-UTIIJYGPSA-N 0.000 description 2
- YJLIKUSWRSEPSM-WGQQHEPDSA-N (2r,3r,4s,5r)-2-[6-amino-8-[(4-phenylphenyl)methylamino]purin-9-yl]-5-(hydroxymethyl)oxolane-3,4-diol Chemical compound C=1C=C(C=2C=CC=CC=2)C=CC=1CNC1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O YJLIKUSWRSEPSM-WGQQHEPDSA-N 0.000 description 2
- ACEAELOMUCBPJP-UHFFFAOYSA-N (E)-3,4,5-trihydroxycinnamic acid Natural products OC(=O)C=CC1=CC(O)=C(O)C(O)=C1 ACEAELOMUCBPJP-UHFFFAOYSA-N 0.000 description 2
- KQZLRWGGWXJPOS-NLFPWZOASA-N 1-[(1R)-1-(2,4-dichlorophenyl)ethyl]-6-[(4S,5R)-4-[(2S)-2-(hydroxymethyl)pyrrolidin-1-yl]-5-methylcyclohexen-1-yl]pyrazolo[3,4-b]pyrazine-3-carbonitrile Chemical compound ClC1=C(C=CC(=C1)Cl)[C@@H](C)N1N=C(C=2C1=NC(=CN=2)C1=CC[C@@H]([C@@H](C1)C)N1[C@@H](CCC1)CO)C#N KQZLRWGGWXJPOS-NLFPWZOASA-N 0.000 description 2
- FQMZXMVHHKXGTM-UHFFFAOYSA-N 2-(1-adamantyl)-n-[2-[2-(2-hydroxyethylamino)ethylamino]quinolin-5-yl]acetamide Chemical compound C1C(C2)CC(C3)CC2CC13CC(=O)NC1=CC=CC2=NC(NCCNCCO)=CC=C21 FQMZXMVHHKXGTM-UHFFFAOYSA-N 0.000 description 2
- HZAXFHJVJLSVMW-UHFFFAOYSA-N 2-Aminoethan-1-ol Chemical compound NCCO HZAXFHJVJLSVMW-UHFFFAOYSA-N 0.000 description 2
- CPXGGWXJNQSFEP-UHFFFAOYSA-N 2-[3-(trifluoromethyl)phenyl]-3,4-dihydropyrazol-5-amine Chemical compound C1CC(N)=NN1C1=CC=CC(C(F)(F)F)=C1 CPXGGWXJNQSFEP-UHFFFAOYSA-N 0.000 description 2
- PYRKKGOKRMZEIT-UHFFFAOYSA-N 2-[6-(2-cyclopropylethoxy)-9-(2-hydroxy-2-methylpropyl)-1h-phenanthro[9,10-d]imidazol-2-yl]-5-fluorobenzene-1,3-dicarbonitrile Chemical compound C1=C2C3=CC(CC(C)(O)C)=CC=C3C=3NC(C=4C(=CC(F)=CC=4C#N)C#N)=NC=3C2=CC=C1OCCC1CC1 PYRKKGOKRMZEIT-UHFFFAOYSA-N 0.000 description 2
- 125000001255 4-fluorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C([H])=C1F 0.000 description 2
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- ISMDILRWKSYCOD-GNKBHMEESA-N C(C1=CC=CC=C1)[C@@H]1NC(OCCCCCCCCCCCNC([C@@H](NC(C[C@@H]1O)=O)C(C)C)=O)=O Chemical compound C(C1=CC=CC=C1)[C@@H]1NC(OCCCCCCCCCCCNC([C@@H](NC(C[C@@H]1O)=O)C(C)C)=O)=O ISMDILRWKSYCOD-GNKBHMEESA-N 0.000 description 2
- 241000700199 Cavia porcellus Species 0.000 description 2
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 2
- 102000004190 Enzymes Human genes 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- RRSNDVCODIMOFX-MPKOGUQCSA-N Fc1c(Cl)cccc1[C@H]1[C@@H](NC2(CCCCC2)[C@@]11C(=O)Nc2cc(Cl)ccc12)C(=O)Nc1ccc(cc1)C(=O)NCCCCCc1cccc2C(=O)N(Cc12)C1CCC(=O)NC1=O Chemical compound Fc1c(Cl)cccc1[C@H]1[C@@H](NC2(CCCCC2)[C@@]11C(=O)Nc2cc(Cl)ccc12)C(=O)Nc1ccc(cc1)C(=O)NCCCCCc1cccc2C(=O)N(Cc12)C1CCC(=O)NC1=O RRSNDVCODIMOFX-MPKOGUQCSA-N 0.000 description 2
- 108010010803 Gelatin Proteins 0.000 description 2
- 102000003820 Lipoxygenases Human genes 0.000 description 2
- 108090000128 Lipoxygenases Proteins 0.000 description 2
- WSMYVTOQOOLQHP-UHFFFAOYSA-N Malondialdehyde Chemical compound O=CCC=O WSMYVTOQOOLQHP-UHFFFAOYSA-N 0.000 description 2
- 241000699670 Mus sp. Species 0.000 description 2
- GLUUGHFHXGJENI-UHFFFAOYSA-N Piperazine Chemical compound C1CNCCN1 GLUUGHFHXGJENI-UHFFFAOYSA-N 0.000 description 2
- 241000700159 Rattus Species 0.000 description 2
- 206010039085 Rhinitis allergic Diseases 0.000 description 2
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 2
- SPXSEZMVRJLHQG-XMMPIXPASA-N [(2R)-1-[[4-[(3-phenylmethoxyphenoxy)methyl]phenyl]methyl]pyrrolidin-2-yl]methanol Chemical compound C(C1=CC=CC=C1)OC=1C=C(OCC2=CC=C(CN3[C@H](CCC3)CO)C=C2)C=CC=1 SPXSEZMVRJLHQG-XMMPIXPASA-N 0.000 description 2
- SMNRFWMNPDABKZ-WVALLCKVSA-N [[(2R,3S,4R,5S)-5-(2,6-dioxo-3H-pyridin-3-yl)-3,4-dihydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl] [[[(2R,3S,4S,5R,6R)-4-fluoro-3,5-dihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-hydroxyphosphoryl]oxy-hydroxyphosphoryl] hydrogen phosphate Chemical compound OC[C@H]1O[C@H](OP(O)(=O)OP(O)(=O)OP(O)(=O)OP(O)(=O)OC[C@H]2O[C@H]([C@H](O)[C@@H]2O)C2C=CC(=O)NC2=O)[C@H](O)[C@@H](F)[C@@H]1O SMNRFWMNPDABKZ-WVALLCKVSA-N 0.000 description 2
- 201000010105 allergic rhinitis Diseases 0.000 description 2
- 229910021529 ammonia Inorganic materials 0.000 description 2
- 239000000043 antiallergic agent Substances 0.000 description 2
- 150000001562 benzopyrans Chemical class 0.000 description 2
- 239000000872 buffer Substances 0.000 description 2
- 229940074360 caffeic acid Drugs 0.000 description 2
- 235000004883 caffeic acid Nutrition 0.000 description 2
- 229910052799 carbon Inorganic materials 0.000 description 2
- 229910052801 chlorine Inorganic materials 0.000 description 2
- QAIPRVGONGVQAS-UHFFFAOYSA-N cis-caffeic acid Natural products OC(=O)C=CC1=CC=C(O)C(O)=C1 QAIPRVGONGVQAS-UHFFFAOYSA-N 0.000 description 2
- 238000004440 column chromatography Methods 0.000 description 2
- 229940125904 compound 1 Drugs 0.000 description 2
- 229940125773 compound 10 Drugs 0.000 description 2
- 229940125797 compound 12 Drugs 0.000 description 2
- 229940126543 compound 14 Drugs 0.000 description 2
- 229940126214 compound 3 Drugs 0.000 description 2
- 229940125877 compound 31 Drugs 0.000 description 2
- 229940127271 compound 49 Drugs 0.000 description 2
- 229940125898 compound 5 Drugs 0.000 description 2
- 229910052731 fluorine Inorganic materials 0.000 description 2
- 239000000499 gel Substances 0.000 description 2
- 239000008273 gelatin Substances 0.000 description 2
- 229920000159 gelatin Polymers 0.000 description 2
- 235000019322 gelatine Nutrition 0.000 description 2
- 235000011852 gelatine desserts Nutrition 0.000 description 2
- RWSXRVCMGQZWBV-WDSKDSINSA-N glutathione Chemical compound OC(=O)[C@@H](N)CCC(=O)N[C@@H](CS)C(=O)NCC(O)=O RWSXRVCMGQZWBV-WDSKDSINSA-N 0.000 description 2
- 150000004820 halides Chemical class 0.000 description 2
- 238000010438 heat treatment Methods 0.000 description 2
- 239000012442 inert solvent Substances 0.000 description 2
- 238000007912 intraperitoneal administration Methods 0.000 description 2
- ZLVXBBHTMQJRSX-VMGNSXQWSA-N jdtic Chemical compound C1([C@]2(C)CCN(C[C@@H]2C)C[C@H](C(C)C)NC(=O)[C@@H]2NCC3=CC(O)=CC=C3C2)=CC=CC(O)=C1 ZLVXBBHTMQJRSX-VMGNSXQWSA-N 0.000 description 2
- 239000010410 layer Substances 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 229940118019 malondialdehyde Drugs 0.000 description 2
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 description 2
- VAMXMNNIEUEQDV-UHFFFAOYSA-N methyl anthranilate Chemical compound COC(=O)C1=CC=CC=C1N VAMXMNNIEUEQDV-UHFFFAOYSA-N 0.000 description 2
- RWIVICVCHVMHMU-UHFFFAOYSA-N n-aminoethylmorpholine Chemical compound NCCN1CCOCC1 RWIVICVCHVMHMU-UHFFFAOYSA-N 0.000 description 2
- 125000001624 naphthyl group Chemical group 0.000 description 2
- IOMMMLWIABWRKL-WUTDNEBXSA-N nazartinib Chemical compound C1N(C(=O)/C=C/CN(C)C)CCCC[C@H]1N1C2=C(Cl)C=CC=C2N=C1NC(=O)C1=CC=NC(C)=C1 IOMMMLWIABWRKL-WUTDNEBXSA-N 0.000 description 2
- 229910052757 nitrogen Inorganic materials 0.000 description 2
- 229910052760 oxygen Inorganic materials 0.000 description 2
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 2
- 125000004194 piperazin-1-yl group Chemical group [H]N1C([H])([H])C([H])([H])N(*)C([H])([H])C1([H])[H] 0.000 description 2
- 239000003755 preservative agent Substances 0.000 description 2
- 230000002265 prevention Effects 0.000 description 2
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 2
- 150000003180 prostaglandins Chemical class 0.000 description 2
- 150000003217 pyrazoles Chemical class 0.000 description 2
- 235000017557 sodium bicarbonate Nutrition 0.000 description 2
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 2
- 238000003756 stirring Methods 0.000 description 2
- 239000012134 supernatant fraction Substances 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- 235000020357 syrup Nutrition 0.000 description 2
- 239000006188 syrup Substances 0.000 description 2
- 238000005406 washing Methods 0.000 description 2
- ASGMFNBUXDJWJJ-JLCFBVMHSA-N (1R,3R)-3-[[3-bromo-1-[4-(5-methyl-1,3,4-thiadiazol-2-yl)phenyl]pyrazolo[3,4-d]pyrimidin-6-yl]amino]-N,1-dimethylcyclopentane-1-carboxamide Chemical compound BrC1=NN(C2=NC(=NC=C21)N[C@H]1C[C@@](CC1)(C(=O)NC)C)C1=CC=C(C=C1)C=1SC(=NN=1)C ASGMFNBUXDJWJJ-JLCFBVMHSA-N 0.000 description 1
- UAOUIVVJBYDFKD-XKCDOFEDSA-N (1R,9R,10S,11R,12R,15S,18S,21R)-10,11,21-trihydroxy-8,8-dimethyl-14-methylidene-4-(prop-2-enylamino)-20-oxa-5-thia-3-azahexacyclo[9.7.2.112,15.01,9.02,6.012,18]henicosa-2(6),3-dien-13-one Chemical compound C([C@@H]1[C@@H](O)[C@@]23C(C1=C)=O)C[C@H]2[C@]12C(N=C(NCC=C)S4)=C4CC(C)(C)[C@H]1[C@H](O)[C@]3(O)OC2 UAOUIVVJBYDFKD-XKCDOFEDSA-N 0.000 description 1
- AOSZTAHDEDLTLQ-AZKQZHLXSA-N (1S,2S,4R,8S,9S,11S,12R,13S,19S)-6-[(3-chlorophenyl)methyl]-12,19-difluoro-11-hydroxy-8-(2-hydroxyacetyl)-9,13-dimethyl-6-azapentacyclo[10.8.0.02,9.04,8.013,18]icosa-14,17-dien-16-one Chemical compound C([C@@H]1C[C@H]2[C@H]3[C@]([C@]4(C=CC(=O)C=C4[C@@H](F)C3)C)(F)[C@@H](O)C[C@@]2([C@@]1(C1)C(=O)CO)C)N1CC1=CC=CC(Cl)=C1 AOSZTAHDEDLTLQ-AZKQZHLXSA-N 0.000 description 1
- ABJSOROVZZKJGI-OCYUSGCXSA-N (1r,2r,4r)-2-(4-bromophenyl)-n-[(4-chlorophenyl)-(2-fluoropyridin-4-yl)methyl]-4-morpholin-4-ylcyclohexane-1-carboxamide Chemical compound C1=NC(F)=CC(C(NC(=O)[C@H]2[C@@H](C[C@@H](CC2)N2CCOCC2)C=2C=CC(Br)=CC=2)C=2C=CC(Cl)=CC=2)=C1 ABJSOROVZZKJGI-OCYUSGCXSA-N 0.000 description 1
- GLGNXYJARSMNGJ-VKTIVEEGSA-N (1s,2s,3r,4r)-3-[[5-chloro-2-[(1-ethyl-6-methoxy-2-oxo-4,5-dihydro-3h-1-benzazepin-7-yl)amino]pyrimidin-4-yl]amino]bicyclo[2.2.1]hept-5-ene-2-carboxamide Chemical compound CCN1C(=O)CCCC2=C(OC)C(NC=3N=C(C(=CN=3)Cl)N[C@H]3[C@H]([C@@]4([H])C[C@@]3(C=C4)[H])C(N)=O)=CC=C21 GLGNXYJARSMNGJ-VKTIVEEGSA-N 0.000 description 1
- IUSARDYWEPUTPN-OZBXUNDUSA-N (2r)-n-[(2s,3r)-4-[[(4s)-6-(2,2-dimethylpropyl)spiro[3,4-dihydropyrano[2,3-b]pyridine-2,1'-cyclobutane]-4-yl]amino]-3-hydroxy-1-[3-(1,3-thiazol-2-yl)phenyl]butan-2-yl]-2-methoxypropanamide Chemical compound C([C@H](NC(=O)[C@@H](C)OC)[C@H](O)CN[C@@H]1C2=CC(CC(C)(C)C)=CN=C2OC2(CCC2)C1)C(C=1)=CC=CC=1C1=NC=CS1 IUSARDYWEPUTPN-OZBXUNDUSA-N 0.000 description 1
- ITOFPJRDSCGOSA-KZLRUDJFSA-N (2s)-2-[[(4r)-4-[(3r,5r,8r,9s,10s,13r,14s,17r)-3-hydroxy-10,13-dimethyl-2,3,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydro-1h-cyclopenta[a]phenanthren-17-yl]pentanoyl]amino]-3-(1h-indol-3-yl)propanoic acid Chemical compound C([C@H]1CC2)[C@H](O)CC[C@]1(C)[C@@H](CC[C@]13C)[C@@H]2[C@@H]3CC[C@@H]1[C@H](C)CCC(=O)N[C@H](C(O)=O)CC1=CNC2=CC=CC=C12 ITOFPJRDSCGOSA-KZLRUDJFSA-N 0.000 description 1
- WWTBZEKOSBFBEM-SPWPXUSOSA-N (2s)-2-[[2-benzyl-3-[hydroxy-[(1r)-2-phenyl-1-(phenylmethoxycarbonylamino)ethyl]phosphoryl]propanoyl]amino]-3-(1h-indol-3-yl)propanoic acid Chemical compound N([C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)O)C(=O)C(CP(O)(=O)[C@H](CC=1C=CC=CC=1)NC(=O)OCC=1C=CC=CC=1)CC1=CC=CC=C1 WWTBZEKOSBFBEM-SPWPXUSOSA-N 0.000 description 1
- QFLWZFQWSBQYPS-AWRAUJHKSA-N (3S)-3-[[(2S)-2-[[(2S)-2-[5-[(3aS,6aR)-2-oxo-1,3,3a,4,6,6a-hexahydrothieno[3,4-d]imidazol-4-yl]pentanoylamino]-3-methylbutanoyl]amino]-3-(4-hydroxyphenyl)propanoyl]amino]-4-[1-bis(4-chlorophenoxy)phosphorylbutylamino]-4-oxobutanoic acid Chemical compound CCCC(NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)[C@@H](NC(=O)CCCCC1SC[C@@H]2NC(=O)N[C@H]12)C(C)C)P(=O)(Oc1ccc(Cl)cc1)Oc1ccc(Cl)cc1 QFLWZFQWSBQYPS-AWRAUJHKSA-N 0.000 description 1
- IWZSHWBGHQBIML-ZGGLMWTQSA-N (3S,8S,10R,13S,14S,17S)-17-isoquinolin-7-yl-N,N,10,13-tetramethyl-2,3,4,7,8,9,11,12,14,15,16,17-dodecahydro-1H-cyclopenta[a]phenanthren-3-amine Chemical compound CN(C)[C@H]1CC[C@]2(C)C3CC[C@@]4(C)[C@@H](CC[C@@H]4c4ccc5ccncc5c4)[C@@H]3CC=C2C1 IWZSHWBGHQBIML-ZGGLMWTQSA-N 0.000 description 1
- HUWSZNZAROKDRZ-RRLWZMAJSA-N (3r,4r)-3-azaniumyl-5-[[(2s,3r)-1-[(2s)-2,3-dicarboxypyrrolidin-1-yl]-3-methyl-1-oxopentan-2-yl]amino]-5-oxo-4-sulfanylpentane-1-sulfonate Chemical compound OS(=O)(=O)CC[C@@H](N)[C@@H](S)C(=O)N[C@@H]([C@H](C)CC)C(=O)N1CCC(C(O)=O)[C@H]1C(O)=O HUWSZNZAROKDRZ-RRLWZMAJSA-N 0.000 description 1
- MPDDTAJMJCESGV-CTUHWIOQSA-M (3r,5r)-7-[2-(4-fluorophenyl)-5-[methyl-[(1r)-1-phenylethyl]carbamoyl]-4-propan-2-ylpyrazol-3-yl]-3,5-dihydroxyheptanoate Chemical compound C1([C@@H](C)N(C)C(=O)C2=NN(C(CC[C@@H](O)C[C@@H](O)CC([O-])=O)=C2C(C)C)C=2C=CC(F)=CC=2)=CC=CC=C1 MPDDTAJMJCESGV-CTUHWIOQSA-M 0.000 description 1
- YQOLEILXOBUDMU-KRWDZBQOSA-N (4R)-5-[(6-bromo-3-methyl-2-pyrrolidin-1-ylquinoline-4-carbonyl)amino]-4-(2-chlorophenyl)pentanoic acid Chemical compound CC1=C(C2=C(C=CC(=C2)Br)N=C1N3CCCC3)C(=O)NC[C@H](CCC(=O)O)C4=CC=CC=C4Cl YQOLEILXOBUDMU-KRWDZBQOSA-N 0.000 description 1
- ZORQXIQZAOLNGE-UHFFFAOYSA-N 1,1-difluorocyclohexane Chemical compound FC1(F)CCCCC1 ZORQXIQZAOLNGE-UHFFFAOYSA-N 0.000 description 1
- FJLUATLTXUNBOT-UHFFFAOYSA-N 1-Hexadecylamine Chemical compound CCCCCCCCCCCCCCCCN FJLUATLTXUNBOT-UHFFFAOYSA-N 0.000 description 1
- ONBQEOIKXPHGMB-VBSBHUPXSA-N 1-[2-[(2s,3r,4s,5r)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]oxy-4,6-dihydroxyphenyl]-3-(4-hydroxyphenyl)propan-1-one Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1OC1=CC(O)=CC(O)=C1C(=O)CCC1=CC=C(O)C=C1 ONBQEOIKXPHGMB-VBSBHUPXSA-N 0.000 description 1
- LCLWEOIMXMEDKX-UHFFFAOYSA-N 1-[3-(trifluoromethyl)phenyl]pyrazol-3-amine Chemical compound N1=C(N)C=CN1C1=CC=CC(C(F)(F)F)=C1 LCLWEOIMXMEDKX-UHFFFAOYSA-N 0.000 description 1
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 1
- ZNHVWPKMFKADKW-UHFFFAOYSA-N 12-HETE Chemical compound CCCCCC=CCC(O)C=CC=CCC=CCCCC(O)=O ZNHVWPKMFKADKW-UHFFFAOYSA-N 0.000 description 1
- ZNHVWPKMFKADKW-ZYBDYUKJSA-N 12-HETE Natural products CCCCC\C=C/C[C@@H](O)\C=C\C=C/C\C=C/CCCC(O)=O ZNHVWPKMFKADKW-ZYBDYUKJSA-N 0.000 description 1
- 238000005160 1H NMR spectroscopy Methods 0.000 description 1
- QIXDHVDGPXBRRD-UHFFFAOYSA-N 2,3,5-trimethylcyclohexa-2,5-diene-1,4-dione Chemical compound CC1=CC(=O)C(C)=C(C)C1=O QIXDHVDGPXBRRD-UHFFFAOYSA-N 0.000 description 1
- SMZOUWXMTYCWNB-UHFFFAOYSA-N 2-(2-methoxy-5-methylphenyl)ethanamine Chemical compound COC1=CC=C(C)C=C1CCN SMZOUWXMTYCWNB-UHFFFAOYSA-N 0.000 description 1
- MLFWVQRFWQERBU-UHFFFAOYSA-N 2-(2H-chromen-2-yl)acetamide Chemical compound O1C(C=CC2=CC=CC=C12)CC(=O)N MLFWVQRFWQERBU-UHFFFAOYSA-N 0.000 description 1
- NIXOWILDQLNWCW-UHFFFAOYSA-N 2-Propenoic acid Natural products OC(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-N 0.000 description 1
- NGNBDVOYPDDBFK-UHFFFAOYSA-N 2-[2,4-di(pentan-2-yl)phenoxy]acetyl chloride Chemical compound CCCC(C)C1=CC=C(OCC(Cl)=O)C(C(C)CCC)=C1 NGNBDVOYPDDBFK-UHFFFAOYSA-N 0.000 description 1
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 1
- YSUIQYOGTINQIN-UZFYAQMZSA-N 2-amino-9-[(1S,6R,8R,9S,10R,15R,17R,18R)-8-(6-aminopurin-9-yl)-9,18-difluoro-3,12-dihydroxy-3,12-bis(sulfanylidene)-2,4,7,11,13,16-hexaoxa-3lambda5,12lambda5-diphosphatricyclo[13.2.1.06,10]octadecan-17-yl]-1H-purin-6-one Chemical compound NC1=NC2=C(N=CN2[C@@H]2O[C@@H]3COP(S)(=O)O[C@@H]4[C@@H](COP(S)(=O)O[C@@H]2[C@@H]3F)O[C@H]([C@H]4F)N2C=NC3=C2N=CN=C3N)C(=O)N1 YSUIQYOGTINQIN-UZFYAQMZSA-N 0.000 description 1
- TVTJUIAKQFIXCE-HUKYDQBMSA-N 2-amino-9-[(2R,3S,4S,5R)-4-fluoro-3-hydroxy-5-(hydroxymethyl)oxolan-2-yl]-7-prop-2-ynyl-1H-purine-6,8-dione Chemical compound NC=1NC(C=2N(C(N(C=2N=1)[C@@H]1O[C@@H]([C@H]([C@H]1O)F)CO)=O)CC#C)=O TVTJUIAKQFIXCE-HUKYDQBMSA-N 0.000 description 1
- ABFPKTQEQNICFT-UHFFFAOYSA-M 2-chloro-1-methylpyridin-1-ium;iodide Chemical compound [I-].C[N+]1=CC=CC=C1Cl ABFPKTQEQNICFT-UHFFFAOYSA-M 0.000 description 1
- RLQZIECDMISZHS-UHFFFAOYSA-N 2-phenylcyclohexa-2,5-diene-1,4-dione Chemical compound O=C1C=CC(=O)C(C=2C=CC=CC=2)=C1 RLQZIECDMISZHS-UHFFFAOYSA-N 0.000 description 1
- 125000000094 2-phenylethyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])C([H])([H])* 0.000 description 1
- MZSAMHOCTRNOIZ-UHFFFAOYSA-N 3-[4-(aminomethyl)-6-(trifluoromethyl)pyridin-2-yl]oxy-N-phenylaniline Chemical compound NCC1=CC(=NC(=C1)C(F)(F)F)OC=1C=C(NC2=CC=CC=C2)C=CC=1 MZSAMHOCTRNOIZ-UHFFFAOYSA-N 0.000 description 1
- 125000003573 5-HETE group Chemical group 0.000 description 1
- 244000215068 Acacia senegal Species 0.000 description 1
- 235000019489 Almond oil Nutrition 0.000 description 1
- 206010002556 Ankylosing Spondylitis Diseases 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical group [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 description 1
- BQXUPNKLZNSUMC-YUQWMIPFSA-N CCN(CCCCCOCC(=O)N[C@H](C(=O)N1C[C@H](O)C[C@H]1C(=O)N[C@@H](C)c1ccc(cc1)-c1scnc1C)C(C)(C)C)CCOc1ccc(cc1)C(=O)c1c(sc2cc(O)ccc12)-c1ccc(O)cc1 Chemical compound CCN(CCCCCOCC(=O)N[C@H](C(=O)N1C[C@H](O)C[C@H]1C(=O)N[C@@H](C)c1ccc(cc1)-c1scnc1C)C(C)(C)C)CCOc1ccc(cc1)C(=O)c1c(sc2cc(O)ccc12)-c1ccc(O)cc1 BQXUPNKLZNSUMC-YUQWMIPFSA-N 0.000 description 1
- UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 description 1
- 241000282472 Canis lupus familiaris Species 0.000 description 1
- 229920002134 Carboxymethyl cellulose Polymers 0.000 description 1
- 241000700198 Cavia Species 0.000 description 1
- 241000931705 Cicada Species 0.000 description 1
- 208000035473 Communicable disease Diseases 0.000 description 1
- 229940126657 Compound 17 Drugs 0.000 description 1
- 229940126639 Compound 33 Drugs 0.000 description 1
- 229940127007 Compound 39 Drugs 0.000 description 1
- 229920002261 Corn starch Polymers 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- 206010052804 Drug tolerance Diseases 0.000 description 1
- 241000283086 Equidae Species 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 108010024636 Glutathione Proteins 0.000 description 1
- 229920000084 Gum arabic Polymers 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 1
- 239000004354 Hydroxyethyl cellulose Substances 0.000 description 1
- 229920000663 Hydroxyethyl cellulose Polymers 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- 206010061216 Infarction Diseases 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 235000010643 Leucaena leucocephala Nutrition 0.000 description 1
- 240000007472 Leucaena leucocephala Species 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 241000699666 Mus <mouse, genus> Species 0.000 description 1
- OPFJDXRVMFKJJO-ZHHKINOHSA-N N-{[3-(2-benzamido-4-methyl-1,3-thiazol-5-yl)-pyrazol-5-yl]carbonyl}-G-dR-G-dD-dD-dD-NH2 Chemical compound S1C(C=2NN=C(C=2)C(=O)NCC(=O)N[C@H](CCCN=C(N)N)C(=O)NCC(=O)N[C@H](CC(O)=O)C(=O)N[C@H](CC(O)=O)C(=O)N[C@H](CC(O)=O)C(N)=O)=C(C)N=C1NC(=O)C1=CC=CC=C1 OPFJDXRVMFKJJO-ZHHKINOHSA-N 0.000 description 1
- CTQNGGLPUBDAKN-UHFFFAOYSA-N O-Xylene Chemical compound CC1=CC=CC=C1C CTQNGGLPUBDAKN-UHFFFAOYSA-N 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 1
- 244000061456 Solanum tuberosum Species 0.000 description 1
- 235000002595 Solanum tuberosum Nutrition 0.000 description 1
- 241000282887 Suidae Species 0.000 description 1
- UHWVSEOVJBQKBE-UHFFFAOYSA-N Trimetazidine Chemical compound COC1=C(OC)C(OC)=CC=C1CN1CCNCC1 UHWVSEOVJBQKBE-UHFFFAOYSA-N 0.000 description 1
- LNUFLCYMSVYYNW-ZPJMAFJPSA-N [(2r,3r,4s,5r,6r)-2-[(2r,3r,4s,5r,6r)-6-[(2r,3r,4s,5r,6r)-6-[(2r,3r,4s,5r,6r)-6-[[(3s,5s,8r,9s,10s,13r,14s,17r)-10,13-dimethyl-17-[(2r)-6-methylheptan-2-yl]-2,3,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydro-1h-cyclopenta[a]phenanthren-3-yl]oxy]-4,5-disulfo Chemical compound O([C@@H]1[C@@H](COS(O)(=O)=O)O[C@@H]([C@@H]([C@H]1OS(O)(=O)=O)OS(O)(=O)=O)O[C@@H]1[C@@H](COS(O)(=O)=O)O[C@@H]([C@@H]([C@H]1OS(O)(=O)=O)OS(O)(=O)=O)O[C@@H]1[C@@H](COS(O)(=O)=O)O[C@H]([C@@H]([C@H]1OS(O)(=O)=O)OS(O)(=O)=O)O[C@@H]1C[C@@H]2CC[C@H]3[C@@H]4CC[C@@H]([C@]4(CC[C@@H]3[C@@]2(C)CC1)C)[C@H](C)CCCC(C)C)[C@H]1O[C@H](COS(O)(=O)=O)[C@@H](OS(O)(=O)=O)[C@H](OS(O)(=O)=O)[C@H]1OS(O)(=O)=O LNUFLCYMSVYYNW-ZPJMAFJPSA-N 0.000 description 1
- 210000001015 abdomen Anatomy 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 239000000205 acacia gum Substances 0.000 description 1
- 235000010489 acacia gum Nutrition 0.000 description 1
- 125000002777 acetyl group Chemical group [H]C([H])([H])C(*)=O 0.000 description 1
- 150000008065 acid anhydrides Chemical class 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 230000007059 acute toxicity Effects 0.000 description 1
- 231100000403 acute toxicity Toxicity 0.000 description 1
- 125000003545 alkoxy group Chemical group 0.000 description 1
- 125000005907 alkyl ester group Chemical group 0.000 description 1
- 201000009961 allergic asthma Diseases 0.000 description 1
- 230000007815 allergy Effects 0.000 description 1
- 239000008168 almond oil Substances 0.000 description 1
- CEGOLXSVJUTHNZ-UHFFFAOYSA-K aluminium tristearate Chemical compound [Al+3].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O CEGOLXSVJUTHNZ-UHFFFAOYSA-K 0.000 description 1
- 229940063655 aluminum stearate Drugs 0.000 description 1
- 150000003927 aminopyridines Chemical class 0.000 description 1
- 230000003042 antagnostic effect Effects 0.000 description 1
- 230000008485 antagonism Effects 0.000 description 1
- 125000005002 aryl methyl group Chemical group 0.000 description 1
- 235000010323 ascorbic acid Nutrition 0.000 description 1
- 229960005070 ascorbic acid Drugs 0.000 description 1
- 239000011668 ascorbic acid Substances 0.000 description 1
- XRWSZZJLZRKHHD-WVWIJVSJSA-N asunaprevir Chemical compound O=C([C@@H]1C[C@H](CN1C(=O)[C@@H](NC(=O)OC(C)(C)C)C(C)(C)C)OC1=NC=C(C2=CC=C(Cl)C=C21)OC)N[C@]1(C(=O)NS(=O)(=O)C2CC2)C[C@H]1C=C XRWSZZJLZRKHHD-WVWIJVSJSA-N 0.000 description 1
- 239000012298 atmosphere Substances 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 230000001363 autoimmune Effects 0.000 description 1
- KGNDCEVUMONOKF-UGPLYTSKSA-N benzyl n-[(2r)-1-[(2s,4r)-2-[[(2s)-6-amino-1-(1,3-benzoxazol-2-yl)-1,1-dihydroxyhexan-2-yl]carbamoyl]-4-[(4-methylphenyl)methoxy]pyrrolidin-1-yl]-1-oxo-4-phenylbutan-2-yl]carbamate Chemical compound C1=CC(C)=CC=C1CO[C@H]1CN(C(=O)[C@@H](CCC=2C=CC=CC=2)NC(=O)OCC=2C=CC=CC=2)[C@H](C(=O)N[C@@H](CCCCN)C(O)(O)C=2OC3=CC=CC=C3N=2)C1 KGNDCEVUMONOKF-UGPLYTSKSA-N 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 210000000621 bronchi Anatomy 0.000 description 1
- 239000006172 buffering agent Substances 0.000 description 1
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 239000001110 calcium chloride Substances 0.000 description 1
- 229910001628 calcium chloride Inorganic materials 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- 229910000389 calcium phosphate Inorganic materials 0.000 description 1
- 235000011010 calcium phosphates Nutrition 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 150000004649 carbonic acid derivatives Chemical class 0.000 description 1
- 150000003857 carboxamides Chemical class 0.000 description 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 1
- 239000001768 carboxy methyl cellulose Substances 0.000 description 1
- 235000010948 carboxy methyl cellulose Nutrition 0.000 description 1
- 239000008112 carboxymethyl-cellulose Substances 0.000 description 1
- 239000005018 casein Substances 0.000 description 1
- BECPQYXYKAMYBN-UHFFFAOYSA-N casein, tech. Chemical compound NCCCCC(C(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(CC(C)C)N=C(O)C(CCC(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(C(C)O)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(COP(O)(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(N)CC1=CC=CC=C1 BECPQYXYKAMYBN-UHFFFAOYSA-N 0.000 description 1
- 235000021240 caseins Nutrition 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 239000000919 ceramic Substances 0.000 description 1
- 239000007795 chemical reaction product Substances 0.000 description 1
- 239000000460 chlorine Substances 0.000 description 1
- 239000003240 coconut oil Substances 0.000 description 1
- 235000019864 coconut oil Nutrition 0.000 description 1
- 230000002860 competitive effect Effects 0.000 description 1
- 229940125758 compound 15 Drugs 0.000 description 1
- 229940126142 compound 16 Drugs 0.000 description 1
- 229940125782 compound 2 Drugs 0.000 description 1
- 229940125810 compound 20 Drugs 0.000 description 1
- 229940126086 compound 21 Drugs 0.000 description 1
- 229940126208 compound 22 Drugs 0.000 description 1
- 229940125833 compound 23 Drugs 0.000 description 1
- 229940125961 compound 24 Drugs 0.000 description 1
- 229940125851 compound 27 Drugs 0.000 description 1
- 229940127204 compound 29 Drugs 0.000 description 1
- 229940125807 compound 37 Drugs 0.000 description 1
- 229940127573 compound 38 Drugs 0.000 description 1
- 229940126540 compound 41 Drugs 0.000 description 1
- 229940125844 compound 46 Drugs 0.000 description 1
- 238000009833 condensation Methods 0.000 description 1
- 230000005494 condensation Effects 0.000 description 1
- 230000008602 contraction Effects 0.000 description 1
- 239000008120 corn starch Substances 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- 125000002704 decyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 239000007884 disintegrant Substances 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 210000003743 erythrocyte Anatomy 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- BEFDCLMNVWHSGT-UHFFFAOYSA-N ethenylcyclopentane Chemical compound C=CC1CCCC1 BEFDCLMNVWHSGT-UHFFFAOYSA-N 0.000 description 1
- 125000001301 ethoxy group Chemical group [H]C([H])([H])C([H])([H])O* 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 210000000416 exudates and transudate Anatomy 0.000 description 1
- 235000019197 fats Nutrition 0.000 description 1
- 239000011790 ferrous sulphate Substances 0.000 description 1
- 235000003891 ferrous sulphate Nutrition 0.000 description 1
- 239000000706 filtrate Substances 0.000 description 1
- 235000013312 flour Nutrition 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 229960003180 glutathione Drugs 0.000 description 1
- 210000000224 granular leucocyte Anatomy 0.000 description 1
- 125000004051 hexyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 239000001257 hydrogen Substances 0.000 description 1
- 229910052739 hydrogen Inorganic materials 0.000 description 1
- 235000019447 hydroxyethyl cellulose Nutrition 0.000 description 1
- 210000003405 ileum Anatomy 0.000 description 1
- 230000007574 infarction Effects 0.000 description 1
- 208000027866 inflammatory disease Diseases 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000010255 intramuscular injection Methods 0.000 description 1
- 238000010253 intravenous injection Methods 0.000 description 1
- 229910052740 iodine Inorganic materials 0.000 description 1
- BAUYGSIQEAFULO-UHFFFAOYSA-L iron(2+) sulfate (anhydrous) Chemical compound [Fe+2].[O-]S([O-])(=O)=O BAUYGSIQEAFULO-UHFFFAOYSA-L 0.000 description 1
- 229910000359 iron(II) sulfate Inorganic materials 0.000 description 1
- 230000000302 ischemic effect Effects 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 235000010445 lecithin Nutrition 0.000 description 1
- 239000000787 lecithin Substances 0.000 description 1
- 229940067606 lecithin Drugs 0.000 description 1
- YEESKJGWJFYOOK-IJHYULJSSA-N leukotriene D4 Chemical compound CCCCC\C=C/C\C=C/C=C/C=C/[C@H]([C@@H](O)CCCC(O)=O)SC[C@H](N)C(=O)NCC(O)=O YEESKJGWJFYOOK-IJHYULJSSA-N 0.000 description 1
- 239000003199 leukotriene receptor blocking agent Substances 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 239000012669 liquid formulation Substances 0.000 description 1
- 210000001853 liver microsome Anatomy 0.000 description 1
- RENRQMCACQEWFC-UGKGYDQZSA-N lnp023 Chemical compound C1([C@H]2N(CC=3C=4C=CNC=4C(C)=CC=3OC)CC[C@@H](C2)OCC)=CC=C(C(O)=O)C=C1 RENRQMCACQEWFC-UGKGYDQZSA-N 0.000 description 1
- 231100000053 low toxicity Toxicity 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 229920000609 methyl cellulose Polymers 0.000 description 1
- 239000004292 methyl p-hydroxybenzoate Substances 0.000 description 1
- 235000010270 methyl p-hydroxybenzoate Nutrition 0.000 description 1
- 239000001923 methylcellulose Substances 0.000 description 1
- LXCFILQKKLGQFO-UHFFFAOYSA-N methylparaben Chemical compound COC(=O)C1=CC=C(O)C=C1 LXCFILQKKLGQFO-UHFFFAOYSA-N 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- XONPDZSGENTBNJ-UHFFFAOYSA-N molecular hydrogen;sodium Chemical compound [Na].[H][H] XONPDZSGENTBNJ-UHFFFAOYSA-N 0.000 description 1
- 125000004573 morpholin-4-yl group Chemical group N1(CCOCC1)* 0.000 description 1
- 239000004570 mortar (masonry) Substances 0.000 description 1
- 208000010125 myocardial infarction Diseases 0.000 description 1
- TTYMURDBXAIXQT-UHFFFAOYSA-N n'-(1,3-dichlorohexyl)methanediimine Chemical compound CCCC(Cl)CC(Cl)N=C=N TTYMURDBXAIXQT-UHFFFAOYSA-N 0.000 description 1
- 230000001338 necrotic effect Effects 0.000 description 1
- 239000002687 nonaqueous vehicle Substances 0.000 description 1
- 230000036963 noncompetitive effect Effects 0.000 description 1
- PIDFDZJZLOTZTM-KHVQSSSXSA-N ombitasvir Chemical compound COC(=O)N[C@@H](C(C)C)C(=O)N1CCC[C@H]1C(=O)NC1=CC=C([C@H]2N([C@@H](CC2)C=2C=CC(NC(=O)[C@H]3N(CCC3)C(=O)[C@@H](NC(=O)OC)C(C)C)=CC=2)C=2C=CC(=CC=2)C(C)(C)C)C=C1 PIDFDZJZLOTZTM-KHVQSSSXSA-N 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 229940094443 oxytocics prostaglandins Drugs 0.000 description 1
- 125000003854 p-chlorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C([H])=C1Cl 0.000 description 1
- 125000000913 palmityl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 238000005502 peroxidation Methods 0.000 description 1
- 239000003208 petroleum Substances 0.000 description 1
- 125000004330 phenothiazin-1-yl group Chemical group [H]N1C2=C(SC3=C1C(*)=C([H])C([H])=C3[H])C([H])=C([H])C([H])=C2[H] 0.000 description 1
- YZTJYBJCZXZGCT-UHFFFAOYSA-N phenylpiperazine Chemical compound C1CNCCN1C1=CC=CC=C1 YZTJYBJCZXZGCT-UHFFFAOYSA-N 0.000 description 1
- 239000008363 phosphate buffer Substances 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- NTTOTNSKUYCDAV-UHFFFAOYSA-N potassium hydride Chemical compound [KH] NTTOTNSKUYCDAV-UHFFFAOYSA-N 0.000 description 1
- 229910000105 potassium hydride Inorganic materials 0.000 description 1
- 235000010232 propyl p-hydroxybenzoate Nutrition 0.000 description 1
- 239000004405 propyl p-hydroxybenzoate Substances 0.000 description 1
- QELSKZZBTMNZEB-UHFFFAOYSA-N propylparaben Chemical compound CCCOC(=O)C1=CC=C(O)C=C1 QELSKZZBTMNZEB-UHFFFAOYSA-N 0.000 description 1
- 235000018102 proteins Nutrition 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 206010039073 rheumatoid arthritis Diseases 0.000 description 1
- 239000013049 sediment Substances 0.000 description 1
- 239000000741 silica gel Substances 0.000 description 1
- 229910002027 silica gel Inorganic materials 0.000 description 1
- 239000000377 silicon dioxide Substances 0.000 description 1
- 235000020374 simple syrup Nutrition 0.000 description 1
- 235000019333 sodium laurylsulphate Nutrition 0.000 description 1
- 235000010199 sorbic acid Nutrition 0.000 description 1
- 239000004334 sorbic acid Substances 0.000 description 1
- 229940075582 sorbic acid Drugs 0.000 description 1
- 239000001593 sorbitan monooleate Substances 0.000 description 1
- 235000011069 sorbitan monooleate Nutrition 0.000 description 1
- 229940035049 sorbitan monooleate Drugs 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 238000010254 subcutaneous injection Methods 0.000 description 1
- 239000000375 suspending agent Substances 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 1
- 238000004809 thin layer chromatography Methods 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
- FAQYAMRNWDIXMY-UHFFFAOYSA-N trichloroborane Chemical compound ClB(Cl)Cl FAQYAMRNWDIXMY-UHFFFAOYSA-N 0.000 description 1
- 238000002525 ultrasonication Methods 0.000 description 1
- 239000003981 vehicle Substances 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
- 239000008096 xylene Substances 0.000 description 1
Landscapes
- Pyrane Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Description
【発明の詳細な説明】
(産業上の利用分野)
本発明は医薬又はその合成中間体として有用な新規な3
.4−ジヒドロ−2H−ベンゾビラン誘導体及び医薬と
して有用な該誘導体の医薬用途に関する。Detailed Description of the Invention (Industrial Field of Application) The present invention provides novel 3.
.. The present invention relates to 4-dihydro-2H-benzobilane derivatives and medical uses of the derivatives useful as pharmaceuticals.
(従来の技術)
近年、アラキドン酸から5−リポキシゲナーゼの作用に
より生成するロイコトリエン類がアレルギー発症因子と
なることが解明されて以来、5リボキンゲナ一ゼ作用阻
害剤及びロイコトリエン拮抗剤についての研究が活発化
している。3−アミノ−1−(3−トリフルオロメチル
フェニル)ピラゾール(BW755C)などのピラゾー
ル誘導体にリボキンゲナーゼ阻害活性のあることが報告
されたが(Biochem、 Phar+5aco1、
第28巻、第1959頁(1979年)参照〕、これら
のピラゾール誘導体の酵素選択性は低い。一方、(12
−ヒドロキン−5,9ドデカツイン−1−イル)トリメ
チルベンゾキノン(^^−861)は5−リボキンゲナ
ーゼの作用を選択的に阻害しロイコトリエンの生成を抑
制することが報告されており(Biochim、 Bi
ophys、^eta。(Prior Art) In recent years, since it has been revealed that leukotrienes produced from arachidonic acid by the action of 5-lipoxygenase are a factor in the development of allergies, research into 5-riboquine enzyme action inhibitors and leukotriene antagonists has become active. ing. It has been reported that pyrazole derivatives such as 3-amino-1-(3-trifluoromethylphenyl)pyrazole (BW755C) have riboquinase inhibitory activity (Biochem, Phar+5aco1,
28, p. 1959 (1979)], the enzyme selectivity of these pyrazole derivatives is low. On the other hand, (12
-Hydroquine-5,9dodecatuin-1-yl)trimethylbenzoquinone (^^-861) has been reported to selectively inhibit the action of 5-riboquine genease and suppress the production of leukotrienes (Biochim, Bi
ophys, ^eta.
第713巻、第470頁(1982年)参照〕臓器梗塞
などの炎症反応の治療薬剤として有望視されている。See Vol. 713, p. 470 (1982)] It is seen as a promising drug for treating inflammatory reactions such as organ infarction.
また、各種虚血性疾患においても活性酸素、リポキシゲ
ナーゼ産物などが障害の進展に重要な関与をしているこ
とが示唆されており、例えば、上述のBW755Gが心
筋梗塞壊死領域の拡大防止に有効であることが示されて
いる[ Prostaglandins。In addition, it has been suggested that active oxygen, lipoxygenase products, etc. play an important role in the progression of the disorder in various ischemic diseases.For example, the above-mentioned BW755G is effective in preventing the expansion of the necrotic area of myocardial infarction. It has been shown that [Prostaglandins.
第24巻、第255頁(1982年)参照〕。本発明者
らの一部も成る種のクロマン化合物が高い5−リポキシ
ゲナーゼ阻害作用を持つことを報告している〔特許出願
公開 昭和62年第169726号公報参照〕。See Vol. 24, p. 255 (1982)]. Some of the present inventors have also reported that certain chroman compounds have a high 5-lipoxygenase inhibitory effect [see Patent Application Publication No. 169726 of 1988].
(発明が解決しようとする課題)
前述のようにアレルギー性の疾患であるアレルギー性喘
息、アレルギー性鼻炎の発症においては5−リポキシゲ
ナーゼの作用によって生成するロイコトリx :/ C
,(L丁C,)、ロイコトリ! :/ D4(LTD4
)などのロイコトリエン類が重要な因子として関与して
いることから、5−リポキシゲナーゼを失活させ、その
作用を阻害する活性を有する薬剤及びロイコトリエンに
対して拮抗作用を有する薬剤の出現が強く望まれている
のが現状である。一方、アレルギー疾叡においてはヒス
タミンの関与も大きいことが知られていることから、抗
ヒスタミン作用を併せ持てば臨床上より有効性の高い喘
息・アレルギー疾患治療薬となり得ることが期待される
。(Problems to be Solved by the Invention) As mentioned above, in the onset of allergic diseases such as allergic asthma and allergic rhinitis, leukotrix:/C is produced by the action of 5-lipoxygenase.
, (Lcho C,), Roy Kotori! :/ D4(LTD4
) and other leukotrienes are involved as important factors, there is a strong desire for the emergence of drugs that have the activity of deactivating 5-lipoxygenase and inhibiting its action, and drugs that have an antagonistic effect on leukotrienes. The current situation is that On the other hand, since it is known that histamine is largely involved in allergic diseases, it is expected that if it also has an antihistamine effect, it can become a clinically more effective therapeutic agent for asthma and allergic diseases.
しかして、本発明の目的は、5−リポキシゲナーゼ阻害
作用とともに抗ヒスタミン作用を併せ持ち、しかも安全
性の高い抗アレルギー剤として有用な新規な化合物及び
その合成中間体を提供することにあり、加えて、各種虚
血性疾患治療剤として期待される脂質過酸化防止作用を
有する新規な化合物、鎮痛剤として有用な鎮痛作用を有
する新規な化合物及びそれらの合成中間体を提供するこ
とにある。本発明の他の目的は医薬として有用な当該新
規な化合物の医薬用途、即ち当該化合物を有効成分とす
る医薬組成物を提供することにある。Therefore, an object of the present invention is to provide a novel compound that has both 5-lipoxygenase inhibitory action and antihistamine action, and is useful as a highly safe antiallergic agent, and its synthetic intermediate. The object of the present invention is to provide a novel compound having a lipid peroxidation inhibitory action that is expected to be used as a therapeutic agent for various ischemic diseases, a new compound having an analgesic action useful as an analgesic, and synthetic intermediates thereof. Another object of the present invention is to provide a pharmaceutical use of the novel compound, which is useful as a medicine, ie, a pharmaceutical composition containing the compound as an active ingredient.
(課題を解決するための手段)
本発明によれば、上記の目的は、(1)一般式(式中、
R1は水素原子又は低級アルキル基を表わし、R″は水
素原子、置換基を有していてもよい直鎖アルキル基、置
換基を存していてもよいアリール基若しくはピリジル基
を表わすか、又はR1とR1が一部゛になって式−(C
Ht)to(CHt)t−で示さで示される基を表わし
、R3は水素原子又は水酸基の保護基を表わし、R′は
水素原子、置換基を有していてもよいアリール基又は置
換基を有していてもよいアラルキル基を表わし、nはO
ll又は2の整数を表わし、mは0又は藍の整数を表わ
す)
で示される3、4−ジヒドロ−2H−ベンゾピラン誘導
体〔以下、3.4−ジヒドロ−2H−ベンゾピラン誘導
体(+)と称することかある〕、及び(2)一般式(1
)においてR3が水素原子を表わすことによつて示され
る3、4−ジヒドロ−2)1−ベンゾビラン誘導体〔下
記一般式(1−1)によって示される誘導体〕の少なく
とも一種を治療上有効量含み、かつ医薬上許容される添
加剤を含む医薬組成物を提供することによって達成され
る。(Means for Solving the Problems) According to the present invention, the above objects are achieved by (1) the general formula (in the formula,
R1 represents a hydrogen atom or a lower alkyl group, and R'' represents a hydrogen atom, a linear alkyl group that may have a substituent, an aryl group or a pyridyl group that may have a substituent, or R1 and R1 become part ゛ and the formula -(C
Ht)to(CHt)t-, R3 represents a hydrogen atom or a hydroxyl group protecting group, and R' represents a hydrogen atom, an aryl group which may have a substituent, or a substituent. represents an optional aralkyl group, n is O
3,4-dihydro-2H-benzopyran derivative [hereinafter referred to as 3,4-dihydro-2H-benzopyran derivative (+)] ], and (2) general formula (1
), wherein R3 represents a hydrogen atom, containing a therapeutically effective amount of at least one type of 3,4-dihydro-2)1-benzobilane derivative [derivative represented by the following general formula (1-1)], and by providing a pharmaceutical composition containing a pharmaceutically acceptable additive.
一般式(1)で示される3、4−ジヒドロ−2H−ベン
ゾビラン誘導体は、次の2つのタイプに分けることがで
きる。The 3,4-dihydro-2H-benzobilane derivative represented by the general formula (1) can be divided into the following two types.
l)一般式
(式中、R1、R′、n及びmは前記定義の通りである
)
で示される3、4−ジヒドロ−211−ベンゾビラン誘
導体〔以下、3.4−ジヒドロ−2■−ベンゾビラン誘
導体(1−1)と称することがある〕。l) 3,4-dihydro-211-benzobilane derivative represented by the general formula (wherein R1, R', n and m are as defined above) [hereinafter referred to as 3,4-dihydro-2-benzobilane may be referred to as derivative (1-1)].
2)一般式
(式中、R,R,X、Y、m及びpは前記定義の通りで
あり、R5は水酸基の保護基を表わす)で示される3、
4〜ジヒドロ−211−ベンゾビラン誘導体〔以下、3
,4−ジヒドロ−2H−ベンゾビラン誘導体(1−2)
と称することがある〕。2) 3 represented by the general formula (wherein R, R, X, Y, m and p are as defined above, and R5 represents a hydroxyl protecting group),
4-dihydro-211-benzobilane derivative [hereinafter referred to as 3
,4-dihydro-2H-benzobilane derivative (1-2)
].
3.4−ジヒドロ−2■−ベンゾビラン誘導体(+−1
)は医薬として、3.4−ノヒドロー211−ベンゾピ
ラン誘導体(1−2)は3.4−ジヒドロ−2H−ベン
ゾビラン誘導体(+−1)の合成中間体として有用であ
る。3.4-dihydro-2■-benzobilane derivative (+-1
) is useful as a medicine, and the 3,4-nohydro-211-benzopyran derivative (1-2) is useful as a synthetic intermediate for the 3,4-dihydro-2H-benzopyran derivative (+-1).
上記一般式におけるR1、R1、R3、R4及びR6を
以下に詳しく説明する。R1, R1, R3, R4 and R6 in the above general formula will be explained in detail below.
R1が表わす低級アルキル基としては、メチル基、エチ
ル基、プロピル基などが挙げられ、R1が表わす直鎖ア
ルキル基としてはメチル基、エチル基、プロピル基、ブ
チル基、ヘキシル基、デシル基、ヘキサデシル基、オク
タデシル基などが挙げられ、この直鎖アルキル基が有し
ていてもよい置換基としてはヒドロキンル基、モルホリ
ノ基又はハロゲン原子で置換されていてもよい4−ベン
ズヒドリルビペラノニル基が挙げられ、ここでハロゲン
原子としてはフッ素原子又は塩素原子などが挙げられる
。アリール基としてはフェニル基、ナフチル基などが挙
げられ、このアリール基が有していてもよい置換基とし
てはカルボキシル基などが挙げられる。R1及びR6の
表わす水酸基の保護基としてはベンジル基、p−メトキ
シベンジル基などのアリールメチル基又はアセチル基、
ベンゾイル基などのアシル基が挙げられ、R4の表わす
アリール基としてはフェニル基、ナフチル基などが挙げ
られ、このアリール基が有していてもよい置喚基として
はフッ素原子、塩素原子、臭素原子などのハロゲン原子
又はメトキシ基、エトキシ基などの低級アルコキシ基が
挙げられ、アラルキル基としてはフッ素原子、塩素原子
などのハロゲン原子を有していてもよいベンズヒドリル
基、メトキシ基、ピリジル基などの置換基を有していて
もよいベンジル基、フェネチル基などが挙げられる。Examples of the lower alkyl group represented by R1 include methyl group, ethyl group, propyl group, etc., and examples of the straight chain alkyl group represented by R1 include methyl group, ethyl group, propyl group, butyl group, hexyl group, decyl group, hexadecyl group. Examples of substituents that this linear alkyl group may have include a hydroquinyl group, a morpholino group, and a 4-benzhydrylbiperanoyl group which may be substituted with a halogen atom. Here, examples of the halogen atom include a fluorine atom and a chlorine atom. Examples of the aryl group include a phenyl group and a naphthyl group, and examples of the substituent that this aryl group may have include a carboxyl group. As the protecting group for the hydroxyl group represented by R1 and R6, an arylmethyl group such as a benzyl group or a p-methoxybenzyl group or an acetyl group,
Examples of the aryl group represented by R4 include a phenyl group and a naphthyl group. Examples of substituent groups that this aryl group may have include a fluorine atom, a chlorine atom, and a bromine atom. Substituted halogen atoms such as methoxy groups, lower alkoxy groups such as ethoxy groups, and aralkyl groups include benzhydryl groups, methoxy groups, pyridyl groups, etc., which may have halogen atoms such as fluorine atoms and chlorine atoms. Examples include a benzyl group and a phenethyl group which may have a group.
3.4−ジヒドロ−2H−ベンゾビラン誘導体(1)の
代表例として次の化合物を挙げることができる。The following compounds can be mentioned as representative examples of the 3.4-dihydro-2H-benzobilane derivative (1).
(1)6−ベンジルオキシ−3,4−ジヒドロ−2゜5
.7.8−テトラメチル−2H−ベンゾピラン−2−イ
ルアセトアミド(化合物1)
(2)N−セチル−“6−ベンジルオキシ−3,4ジヒ
ドロ−2,5,7,8−テトラメチル−2日−ペンゾピ
ラン−2−イルアセトアミド(化合物(3)N−(2−
モルフォリノエチル)−6−ベンジルオキシ−3,4−
ジヒドロ−2,5,7,8−テトラメチル−2H−ベン
ゾピラン−2−イルアセトアミド(化合物3)
(4)N−(4−フェニルピペラジン−1−イル)−6
−ベンジルオキシ−3,4−ジヒドロ−2゜5.7.8
−テトラメチル−2H−ベンゾビラン−2−イルアセト
アミド(化合物4)
(5) 3.4−ジヒドロ−6−ヒドロキシ−2,5
,78−テトラメチル−2■−ベンゾピラン−2−イル
アセトアミド(化合物5)
(6) N−セチに−3,4−ジヒドロ−6−ヒVロ
キシ−2,5,7,8−テトラメチル−2H−ベンゾピ
ラン−2−イルアセトアミド(化合物6)(7)N−(
2−モルフォリノエチル) −3,4ジヒドロ−6−ヒ
ドロキシ−2,5,7,8−テトラメチル−2H−ベン
ゾビラン−2−イルアセトアミド(化合物7)
(8)N−(4−フェニルピペラジン−1−イル)−3
,4−ジヒドロ−6−ヒドロキシ−2,5,7゜8−テ
トラメチル−2H−ベンゾビラン−2=イルアセトアミ
ド(化合物8)
(9)N−(2−ヒドロキシエチル) −3,4−ジヒ
ドロ−6−ヒドロキシ−2,5,7,l1l−テトラメ
チル−2H−ベンゾビラン−2−イルカルボキサミド(
化合物9)
(to) 3.4−ジヒドロ−6−ヒドロキシ−2,
5,78−テトラメチル−2−[2−(4−(2,3゜
4−トリメトキシベンジル)ピペラジン−1−イルカル
ボニル〕エチル]−2)1−ベンゾビラン(化合物10
)
(11) 6−アセドキンー3,4−ジヒドロ−2,
5,78−テトラメチル−2−((4−フェニルピペラ
ジン−1−イル)カルボニル)ベンゾビラン(化合物I
I)
(12)N−(2−モルフォリノエチル)−6−アセト
キシ−3,4−ジヒドロ−2,5,7,8−テトラメチ
ル−2■−ベンゾビラン−2−イルカルボキサミド(化
合物12)
(13) 3.4−ジヒドロ−6−ヒドロキン−2,
5,7゜8−テトラメチル−2−((4−フェニルピペ
ラジン−1−イル)カルボニル〕ベンゾピラン(化合物
13)
(14)N−(2−モルフォリノエチル) −3,4−
ジヒドロ−6−ヒドロキシ−2,5,7,8−テトラメ
チル−2H−ベンゾビラン−2−イルカルボキサミド(
化合物14)
(+5)N−(3−ピリジル)−6−ベンノルオキソ−
3゜4−ジヒドロ−2,5,7,11−テトラメチル−
2■−ベンゾビラン−2−イルアセトアミド(化合物1
5)
(+6) N−フェニル−6−ベンジルオキシ−3,
4ノヒドロー2.5.7.8−テトラメチル−211ベ
ンゾビラン−2−イルアセトアミド(化合物16)
(17) 6−ベンジルオキシ−3,4−ジヒドロ−
2〔(フェノチアジン−1−イル)カルボニルメチル)
−2,5,7,8−テトラメチル−2Hベンゾピラン(
化合物17)
(18) 6−ベンジルオキシ−2−(4−ジフェニ
ルメチルピペラジン−1−イル)カルボニルメチル−3
,4−ジヒドロ−2,5,7,8−テトラメチル−2H
−ベンゾビラン(化合物18)(19) 6−ベンジ
ルオキシ−2−[4−(ビス(4−フルオロフェニル)
メチルコピペラジン−1−イル]カルボニルメチル−3
,4−ジヒドロ−2,5,7,8−テトラメチル−2H
−ベンゾビラン(化合物19)
(20) 8−ベンジルオキシ−2−〔4−フェニル
(2−ピリジル)メチルビペラジン−1−イル〕カルボ
ニルメチルー3.4−ジヒドロ−2゜5.7.8−テト
ラメチル−2H−ベンゾビラン(化合物20)
(’21) N−(2−(4−ジフェニルメチルピペ
ラジン−1−イル)エチル〕−6−ベンノルオキシ−3
,4−ジヒドロ−2,5,7,8−テトラメチル−2H
−ベンゾビラン−2−イルアセトアミド(化合物21)
(!2)N−[2−[4−(ビス(4−フルオロフェニ
ル)メチルコピペラジン−1−イルコニチル]−6−ベ
ンジルオキシ−3,4−ジヒドロ−2,5,7,8−テ
トラメチル−2H−ベンゾビラン−2−イルアセトアミ
ド(化合物22)(23) N−[2−[4−((4
−クロロフェニル)フェニルメチル〕ピペラジン=1−
イル]エチルコー6−ペンジル才キシ−3,4−ジヒド
ロ−2,5,?、8−テトラメチルー2H−ベンゾビラ
ン−2−イルアセトアミド(化合物23)(24)N−
(3−(4−ジフェニルメチルピペラジン−1−イル)
プロピル)−6−ベンジルオキシ−3,4−ジヒドロ−
2,5,7,8−テトラメチル−2H−ベンゾビラン−
2−イルアセトアミド(化合物24)
(25) 6−ベンジルオキシ−3,4−ジヒドロ−
2モルフォリノカルボニルメチル−2,5,7,8−テ
トラメチル−2H−ベンゾピラン(化合物(26)
6−ベンジルオキシ−3,4−ジヒドa−2=チオモル
フォリノカルボニルメチル−2,5゜7.8−テトラメ
チル−2H−ベンゾピラン(化合物26)
(27) e−ベンジルオキシ−3,4−ノヒドロー
2−(1−ピペラジニル)カルボニルメチル−2,5,
7,8−テトラメチル−211−ベンゾビラン(化合物
27)
(2g) 6−ベンジルオキシ−2−(4−ベンジル
ピペラジン−1−イル)カルボニルメチル34−ジヒド
ロ−2,5,7,8−テトラメチル2+1−ベンゾビラ
ン(化合物28)
(29) 6−ペンノルオキシ−3゜4−ジヒドロ−
2−[4−(2−フェニルエチル)ピペラジン−1−イ
ル〕カルボニルメチル−2,5,7,8テトラメチル−
2H−ベンゾビラン(化合物29)(30) N−メ
チル−N−(2−(4−ジフェニルメチルピペラジン−
1−イル)エチル〕−6−ベンジルオキシ−3,4−ジ
ヒドロ−2,S、1゜8−テトラメチル−2トベンゾピ
ラン−2=イルアセトアミド(化合物30)
(31) N−(3−ピリジル)−3,4−ジヒドロ
−6−ヒドロキシ−2,5,7,8−テトラメチル−2
日−ペンゾピラン−2−イルアセトアミド(化合物31
)
(32) N−フェニル−3,4−ジヒドロ−6−ヒ
ドロキシ−2,5,7,8−テトラメチル−2H−ベン
ゾピラン−2−イルアセトアミド(化合物32)(33
) 3.4−ジヒドロ−2−〔(フェノデアノン−1
−イル)カルボニルメチル〕−6−ヒドロキシ−2,5
,7,8−テトラメチル−211−ベンゾビラン(化合
物33)
(34) 2−(4−ジフェニルメチルビペラジン−
1−イル)カルボニルメチル−3,4−ジヒドロ6−ヒ
ドロキシ−2,5,7,8−テトラメチル−2H−ベン
ゾピラン(化合物34)
(35) 2−(4−ビス(4〜フルオロフエニル)
メチルビペラジン−1−イル〕カルボニルメチルー3,
4−ノヒドロー6−ヒドロキン−2,5゜7.8−テト
ラメチル−2H−ベンゾビラン(化合物35)
(3B) 2−(4−フェニル(2−ピリジル)メチ
ルビペラジン−1−イル〕カルボニルメチル−3,4−
’ジヒドロー6−ヒドロキシー2.5,1,8−テトラ
メチル−2H−ベンゾビラン(化合物(37)N−(2
−(4−ジフェニルメチルピペラジン−1−イル)エチ
ル)−3,4−ジヒドロ6−ヒドロキシ−2,5,7,
,8−テトラメチル−2H−ベンゾビラン−2−イルア
セトアミド(化合物37)
(38) N−[2−(4−ビス(4−フルオロフェ
ニル)メチルビペラジン−1−イル〕エチル]13.4
−ジヒドロ−6−ヒドロキシ−2,5,7゜8−テトラ
メチル−2H−ベンゾビラン−2−イルアセトアミド(
化合物38)
(39)N−[2−(4−(4−クロロフェニル)フェ
ニルメチルピペラジン−1−イル〕エチル]−3,4−
ジヒドロ−6−ヒドロキシ−2゜5.7.8−テトラメ
チル−2H−ベンゾピラン−2−イルアセトアミド(化
合物39)
(4G)N−(3−(4−ジフェニルメチルビペラジン
−1−イル)プロピル)−3,4−ジヒドロ−6−ヒド
ロキシ−2,5,?、8−テトラメチル7211−ベン
ゾピラン−2−イルアセトアミド(化合物40)
(41) 3.4−ジヒドロ−2−モルフォリノカル
ボニルメチル−6−ヒドロキシ−2,5,7,8−テト
ラメチル−2H−ベンゾビラン(化合物41)(42)
3.4−ジヒドロ−6−ヒドロキシ−2−チオモル
フォリノカルボニルメチル−2,5,7,8−テトラメ
チル−2H−ベンゾピラン(化合物(43) 3.4
−ジヒドロ−6−ヒドロキシ−2−(l−ピペラジニル
)カルボニルメチル−2,5,7゜8−テトラメチル−
2H−ベンゾピラン(化合物43)
(44) 2−(4・−ベンジルピペラジン−1−イ
ル)カルボニルメチル−3,4−ジヒドロ−6−ヒドロ
キシ−2,5,7,8−テトラメチル−2H−ベンゾピ
ラン(化合物44)
(45) 3.4−ジヒドロ−6−ヒドロキシ−2−
〔4−(2−フェニルエチル)ピペラジン−1イル〕カ
ルボニルメチル−2,5,7,8−テトラメチル−2H
−ベンゾピラン(化合物45)(46) N−メチル
−N−(2−(4−ジフェニルメチルピペラジン−1−
イル)エチル〕−3゜4−ジヒドロ−6−ヒドロキシ−
2,5,?、8テトラメチルー2H−ベンゾピラン−2
−イルアセトアミド(化合物46)
(47)N−(2−カルボキシフェニル)−34−ジヒ
ドロ−6−ヒドロキシ−2,5,7,8−テトラメチル
−2H−ベンゾピラン−2−イルアクリルアミド(化合
物47)
(48)N−(2−カルボン酸フェニル) −3,4ジ
ヒドロ−6−ヒドロキシ−2,5,7,8−テトラメチ
ル−211−ベンゾピラン−2−イルアセトアミド(化
合物48)
(49) 6−ベンジルオキシ−2−(4−ジフェニ
ルメチルピペラジン−1−イル)カルボニルエチル)−
3,4−ジヒドロ−2,5,7,8−テトラメチル−2
日−ベンゾピラン(化合物49)(50) 2−(4
−ジフェニルメチルビペラジン−lイル)カルボニルエ
チル−3,4−ジヒドロ−6−ヒドロキシ−2,5,7
8−テトラメチル2H−ベンゾピラン(化合物5O)
3.4−ジヒドロ−2H−ベンゾピラン誘導体(+)は
一般式(n)で示されるカルボン酸〔以下、カルボン酸
(II)と称することがある〕又はその反応性誘導体と
一般式(III)で示されるアミン〔以下、アミン(I
II)と称することがある〕とを反応させることにより
容易に製造される。カルボン酸(II)の反応性誘導体
としては低級アルキルエステル、酸ハライド、混合酸無
水物などが挙げられる。カルボン酸(n)又はその反応
性誘導体とアミン(III)との反応は、従来知られて
いる一般的なアミド合成反応条件下にて行なうことがで
きるが、以下にそのアミド合成反応の代表例を示す。(1) 6-benzyloxy-3,4-dihydro-2゜5
.. 7.8-Tetramethyl-2H-benzopyran-2-ylacetamide (compound 1) (2) N-cetyl-6-benzyloxy-3,4dihydro-2,5,7,8-tetramethyl-2 days -penzopyran-2-ylacetamide (compound (3) N-(2-
Morpholinoethyl)-6-benzyloxy-3,4-
Dihydro-2,5,7,8-tetramethyl-2H-benzopyran-2-ylacetamide (compound 3) (4) N-(4-phenylpiperazin-1-yl)-6
-benzyloxy-3,4-dihydro-2゜5.7.8
-Tetramethyl-2H-benzobylan-2-ylacetamide (compound 4) (5) 3.4-dihydro-6-hydroxy-2,5
,78-tetramethyl-2■-benzopyran-2-ylacetamide (compound 5) (6) N-ceti-3,4-dihydro-6-hydroxy-2,5,7,8-tetramethyl- 2H-benzopyran-2-ylacetamide (compound 6) (7) N-(
2-morpholinoethyl) -3,4dihydro-6-hydroxy-2,5,7,8-tetramethyl-2H-benzobilan-2-ylacetamide (compound 7) (8) N-(4-phenylpiperazine- 1-yl)-3
,4-dihydro-6-hydroxy-2,5,7゜8-tetramethyl-2H-benzobilane-2=ylacetamide (compound 8) (9) N-(2-hydroxyethyl)-3,4-dihydro- 6-hydroxy-2,5,7,l1l-tetramethyl-2H-benzobilan-2-ylcarboxamide (
Compound 9) (to) 3,4-dihydro-6-hydroxy-2,
5,78-tetramethyl-2-[2-(4-(2,3゜4-trimethoxybenzyl)piperazin-1-ylcarbonyl]ethyl]-2) 1-benzobilane (compound 10
) (11) 6-acedoquine-3,4-dihydro-2,
5,78-tetramethyl-2-((4-phenylpiperazin-1-yl)carbonyl)benzobilane (Compound I
I) (12) N-(2-morpholinoethyl)-6-acetoxy-3,4-dihydro-2,5,7,8-tetramethyl-2■-benzobilan-2-ylcarboxamide (compound 12) ( 13) 3.4-dihydro-6-hydroquine-2,
5,7゜8-tetramethyl-2-((4-phenylpiperazin-1-yl)carbonyl]benzopyran (compound 13) (14) N-(2-morpholinoethyl) -3,4-
Dihydro-6-hydroxy-2,5,7,8-tetramethyl-2H-benzobilan-2-ylcarboxamide (
Compound 14) (+5)N-(3-pyridyl)-6-bennoroxo-
3゜4-dihydro-2,5,7,11-tetramethyl-
2■-benzobilan-2-ylacetamide (compound 1
5) (+6) N-phenyl-6-benzyloxy-3,
4-nohydro2.5.7.8-tetramethyl-211benzobilan-2-ylacetamide (compound 16) (17) 6-benzyloxy-3,4-dihydro-
2 [(phenothiazin-1-yl)carbonylmethyl)
-2,5,7,8-tetramethyl-2H benzopyran (
Compound 17) (18) 6-benzyloxy-2-(4-diphenylmethylpiperazin-1-yl)carbonylmethyl-3
,4-dihydro-2,5,7,8-tetramethyl-2H
-benzobilane (compound 18) (19) 6-benzyloxy-2-[4-(bis(4-fluorophenyl)
methylcopiperazin-1-yl]carbonylmethyl-3
,4-dihydro-2,5,7,8-tetramethyl-2H
-benzobilane (compound 19) (20) 8-benzyloxy-2-[4-phenyl(2-pyridyl)methylbiperazin-1-yl]carbonylmethyl-3.4-dihydro-2°5.7.8-tetramethyl -2H-benzobilane (compound 20) ('21) N-(2-(4-diphenylmethylpiperazin-1-yl)ethyl]-6-benoloxy-3
,4-dihydro-2,5,7,8-tetramethyl-2H
-Benzobylan-2-ylacetamide (compound 21) (!2)N-[2-[4-(bis(4-fluorophenyl)methylcopiperazin-1-ylconityl]-6-benzyloxy-3,4-dihydro -2,5,7,8-tetramethyl-2H-benzobilan-2-ylacetamide (compound 22) (23) N-[2-[4-((4
-chlorophenyl)phenylmethyl]piperazine=1-
yl]ethyl-6-penzyl-3,4-dihydro-2,5,? , 8-tetramethyl-2H-benzobilan-2-ylacetamide (compound 23) (24) N-
(3-(4-diphenylmethylpiperazin-1-yl)
propyl)-6-benzyloxy-3,4-dihydro-
2,5,7,8-tetramethyl-2H-benzobilane-
2-ylacetamide (compound 24) (25) 6-benzyloxy-3,4-dihydro-
2morpholinocarbonylmethyl-2,5,7,8-tetramethyl-2H-benzopyran (compound (26)
6-benzyloxy-3,4-dihydro a-2=thiomorpholinocarbonylmethyl-2,5°7.8-tetramethyl-2H-benzopyran (compound 26) (27) e-benzyloxy-3,4- nohydro-2-(1-piperazinyl)carbonylmethyl-2,5,
7,8-tetramethyl-211-benzobilane (compound 27) (2g) 6-benzyloxy-2-(4-benzylpiperazin-1-yl)carbonylmethyl 34-dihydro-2,5,7,8-tetramethyl 2+1-benzobilane (compound 28) (29) 6-pennoloxy-3゜4-dihydro-
2-[4-(2-phenylethyl)piperazin-1-yl]carbonylmethyl-2,5,7,8tetramethyl-
2H-benzobilane (compound 29) (30) N-methyl-N-(2-(4-diphenylmethylpiperazine-
1-yl)ethyl]-6-benzyloxy-3,4-dihydro-2,S, 1°8-tetramethyl-2tobenzopyran-2=ylacetamide (compound 30) (31) N-(3-pyridyl) -3,4-dihydro-6-hydroxy-2,5,7,8-tetramethyl-2
-penzopyran-2-ylacetamide (compound 31
) (32) N-phenyl-3,4-dihydro-6-hydroxy-2,5,7,8-tetramethyl-2H-benzopyran-2-ylacetamide (compound 32) (33
) 3.4-dihydro-2-[(phenodeanone-1
-yl)carbonylmethyl]-6-hydroxy-2,5
,7,8-tetramethyl-211-benzobilane (compound 33) (34) 2-(4-diphenylmethylbiperazine-
1-yl)carbonylmethyl-3,4-dihydro6-hydroxy-2,5,7,8-tetramethyl-2H-benzopyran (compound 34) (35) 2-(4-bis(4-fluorophenyl)
Methylbiperazin-1-yl]carbonylmethyl-3,
4-Nohydro-6-hydroquine-2,5゜7.8-tetramethyl-2H-benzobilane (compound 35) (3B) 2-(4-phenyl(2-pyridyl)methylbiperazin-1-yl]carbonylmethyl-3, 4-
'Dihydro-6-hydroxy-2,5,1,8-tetramethyl-2H-benzobilane (compound (37) N-(2
-(4-diphenylmethylpiperazin-1-yl)ethyl)-3,4-dihydro6-hydroxy-2,5,7,
,8-tetramethyl-2H-benzobylan-2-ylacetamide (compound 37) (38) N-[2-(4-bis(4-fluorophenyl)methylbiperazin-1-yl]ethyl]13.4
-dihydro-6-hydroxy-2,5,7゜8-tetramethyl-2H-benzobilan-2-ylacetamide (
Compound 38) (39) N-[2-(4-(4-chlorophenyl)phenylmethylpiperazin-1-yl]ethyl]-3,4-
Dihydro-6-hydroxy-2゜5.7.8-tetramethyl-2H-benzopyran-2-ylacetamide (compound 39) (4G)N-(3-(4-diphenylmethylbiperazin-1-yl) propyl)-3,4-dihydro-6-hydroxy-2,5,? , 8-tetramethyl 7211-benzopyran-2-ylacetamide (compound 40) (41) 3.4-dihydro-2-morpholinocarbonylmethyl-6-hydroxy-2,5,7,8-tetramethyl-2H- Benzobilane (compound 41) (42)
3.4-dihydro-6-hydroxy-2-thiomorpholinocarbonylmethyl-2,5,7,8-tetramethyl-2H-benzopyran (compound (43) 3.4
-dihydro-6-hydroxy-2-(l-piperazinyl)carbonylmethyl-2,5,7゜8-tetramethyl-
2H-benzopyran (compound 43) (44) 2-(4-benzylpiperazin-1-yl)carbonylmethyl-3,4-dihydro-6-hydroxy-2,5,7,8-tetramethyl-2H-benzopyran (Compound 44) (45) 3.4-dihydro-6-hydroxy-2-
[4-(2-phenylethyl)piperazin-1yl]carbonylmethyl-2,5,7,8-tetramethyl-2H
-benzopyran (compound 45) (46) N-methyl-N-(2-(4-diphenylmethylpiperazine-1-
yl)ethyl]-3゜4-dihydro-6-hydroxy-
2, 5,? , 8tetramethyl-2H-benzopyran-2
-ylacetamide (compound 46) (47) N-(2-carboxyphenyl)-34-dihydro-6-hydroxy-2,5,7,8-tetramethyl-2H-benzopyran-2-ylacrylamide (compound 47) (48) N-(2-carboxylic acid phenyl) -3,4 dihydro-6-hydroxy-2,5,7,8-tetramethyl-211-benzopyran-2-ylacetamide (compound 48) (49) 6- Benzyloxy-2-(4-diphenylmethylpiperazin-1-yl)carbonylethyl)-
3,4-dihydro-2,5,7,8-tetramethyl-2
Day-benzopyran (compound 49) (50) 2-(4
-diphenylmethylbiperazin-lyl)carbonylethyl-3,4-dihydro-6-hydroxy-2,5,7
8-tetramethyl 2H-benzopyran (compound 5O) 3.4-dihydro-2H-benzopyran derivative (+) is a carboxylic acid represented by general formula (n) [hereinafter sometimes referred to as carboxylic acid (II)] or The reactive derivative and the amine represented by the general formula (III) [hereinafter referred to as amine (I
II)]. Examples of reactive derivatives of carboxylic acid (II) include lower alkyl esters, acid halides, and mixed acid anhydrides. The reaction between carboxylic acid (n) or its reactive derivative and amine (III) can be carried out under conventionally known general amide synthesis reaction conditions. Representative examples of the amide synthesis reaction are shown below. shows.
(1)カルボン酸とアミンとの縮合 きる。(1) Condensation of carboxylic acid and amine Wear.
(2)カルボン酸エステルとアミンの反応(n)
(nl)
(It/) (Ill)(式中、R1、
R1、R3、n及びmは前記定義の通りであり、R3は
水素原子又は水酸基の保護基を表わす)
カルボン酸(TI)とアミン(III)とを無溶媒又は
反応に関与しない溶媒中で150〜250℃に加熱する
か、又は酢酸エチル、テトラヒドロフラン、塩化メチレ
ン、クロロホルム等の不活性溶媒中で、例えばジシクロ
へキシルカルボジイミド、若しくはヨウ化 2−クロル
−1−メチルピリジニウムとトリエチルアミンなどの縮
合剤の存在下に約θ℃ないしは加温下の温度で反応させ
た後、必要に応じ水酸基の保護基を除去することにより
3.4−ジヒドロ−211−ベンゾピラン誘導体(1)
を得ることかで(式中、R1、R3、R3、n及びmは
前記定義の通りであり、R3は水素原子又は水酸基の保
護基を表わし、R@は低級アルキル基を表わす)一般式
(IV)で示されるカルボン酸エステル〔以下、カルボ
ン酸エステル(IV)と称することがある〕とアミン(
III)とを無溶媒又は反応に関与しない溶媒中で15
0〜250℃に加熱した後、必要に応じ水酸基の保護基
を除去することにより3.4−ジヒドロ−2H−ベンゾ
ピラン誘導体(1)を得ることができる。(2) Reaction of carboxylic acid ester and amine (n)
(nl) (It/) (Ill) (wherein R1,
R1, R3, n, and m are as defined above, and R3 represents a hydrogen atom or a hydroxyl group protecting group.) Carboxylic acid (TI) and amine (III) are heated to 150 ml without a solvent or in a solvent that does not participate in the reaction. of a condensing agent such as dicyclohexylcarbodiimide or 2-chloro-1-methylpyridinium iodide and triethylamine in an inert solvent such as ethyl acetate, tetrahydrofuran, methylene chloride, or chloroform. 3,4-dihydro-211-benzopyran derivative (1) by reacting at a temperature of about θ°C or heating in the presence of the compound, and then removing the protecting group of the hydroxyl group as necessary.
(wherein R1, R3, R3, n and m are as defined above, R3 represents a hydrogen atom or a hydroxyl group protecting group, and R@ represents a lower alkyl group) The carboxylic acid ester represented by IV) [hereinafter sometimes referred to as carboxylic acid ester (IV)] and the amine (
III) without solvent or in a solvent that does not participate in the reaction.
After heating to 0 to 250°C, 3,4-dihydro-2H-benzopyran derivative (1) can be obtained by removing the hydroxyl protecting group if necessary.
(3)カルボン酸ハライドとアミンの反応(V)
(III)
(+)
(式中、R1、R1、R3、R5、n及びmは前記定義
の通りであり、Xはハロゲン原子を表わす)一般式(V
)で示されるカルボン酸ハライド〔以下、カルボン酸ハ
ライド(V)と称することがある〕とアミン(I[l)
とを塩化メチレン、クロロホルム、トルエン、酢酸エチ
ルなどの不活性溶媒中で該酸ハライドに対して約1.0
当mないしは溶媒量のピリジン、トリエチルアミンなど
の第三級アミンの存在下、約り℃〜室温で反応させ必要
に応じ水酸基の保護基を除去することにより384−ジ
ヒドロ〜2)1−ベンゾピラン誘導体(1)を得ること
ができる。(3) Reaction of carboxylic acid halide and amine (V)
(III) (+) (wherein, R1, R1, R3, R5, n and m are as defined above, and X represents a halogen atom) General formula (V
) [hereinafter sometimes referred to as carboxylic acid halide (V)] and amine (I[l)
and about 1.0 to the acid halide in an inert solvent such as methylene chloride, chloroform, toluene, or ethyl acetate.
The 384-dihydro-2) 1-benzopyran derivative ( 1) can be obtained.
上記のアミド合成反応により得られた3、4−ジヒドロ
−211−ベンゾピラン誘導体(1)の分離精製は通常
の方法により行なうことができる。例えば、反応混合物
に水を加え、次いで酢酸エチルなどで抽出し、抽出液を
水洗、乾燥した後、溶媒を留去し、その残渣を例えばカ
ラムクロマトグラフィーに付すことにより3,4−ジヒ
ドロ−2H−ベンゾピラン誘導体(1)を分離取得する
ことができる。The 3,4-dihydro-211-benzopyran derivative (1) obtained by the above amide synthesis reaction can be separated and purified by a conventional method. For example, water is added to the reaction mixture, followed by extraction with ethyl acetate, etc., the extract is washed with water, dried, the solvent is distilled off, and the residue is subjected to column chromatography, for example, to obtain 3,4-dihydro-2H - The benzopyran derivative (1) can be separated and obtained.
カルボン酸(II)は公知化合物であり、カルボン酸エ
ステル(IV)及びカルボン酸ハライド(V)は対応す
るカルボン酸(IT)より常法に従い製造することがで
きる。Carboxylic acid (II) is a known compound, and carboxylic acid ester (IV) and carboxylic acid halide (V) can be produced from the corresponding carboxylic acid (IT) according to a conventional method.
3.4−ジヒドロ−2H〜ベンゾピラン誘導体(1)は
クロマン骨格の2位に不斉炭素原子を有しており、その
不斉炭素原子に基づく2種の光学異性体(対掌体)を有
する。また、当該3.4−ジヒドロ−2H−ベンゾビラ
ン誘導体が不斉炭素原子を2個以上存する場合にはこれ
らの不斉炭素原子に由来するジアステレオマーを有する
。これらの異性体はそれぞれ文献公知の対応する光学活
性な化合物を原料として用いて、前記の方法(1)〜(
3)に従って反応及び分離、精製を行なうことにより取
得することができる。3.4-dihydro-2H~benzopyran derivative (1) has an asymmetric carbon atom at the 2-position of the chroman skeleton, and has two types of optical isomers (antipodes) based on the asymmetric carbon atom. . Furthermore, when the 3,4-dihydro-2H-benzobilane derivative has two or more asymmetric carbon atoms, it has diastereomers derived from these asymmetric carbon atoms. These isomers can be obtained by the methods (1) to (1) using the corresponding optically active compounds known in the literature as raw materials.
It can be obtained by performing the reaction, separation, and purification according to 3).
以下、本発明の3,4−ジヒドロ−2H−ベンゾピラン
誘導体(1−1)についての5−リポキシゲナーゼ作用
阻害活性、抗ヒスタミン作用、脂質過酸化防止作用及び
鎮痛作用の試験及びそれらの結果を示す。Below, tests on the 5-lipoxygenase action inhibitory activity, antihistamine action, lipid peroxidation prevention action and analgesic action of the 3,4-dihydro-2H-benzopyran derivative (1-1) of the present invention and their results will be shown.
試験例1
5−リポキシゲナーゼ作用阻害活性
縁」1
越智らの方法(J、 Bio1、 Chew、、第25
8巻、第5754〜5758頁(1983年)参照〕に
準じて、モルモット腹腔多形核白血球105.0OOX
g上清首分を調製し、アラキドン酸からの5−ヒドロキ
シエイコサテトラエン酸(5−HETE)産生能を測定
した。Test Example 1 5-Lipoxygenase action inhibitory activity 1 Method of Ochi et al. (J, Bio1, Chew, 25th
8, pp. 5754-5758 (1983)], guinea pig peritoneal polymorphonuclear leukocytes 105.0OOX
g A supernatant fraction was prepared, and the ability to produce 5-hydroxyeicosatetraenoic acid (5-HETE) from arachidonic acid was measured.
体重的500 gの雄性モルモットに1/101 (I
O++1/100g体重)の2%カゼイン溶液を腹腔内
注射し、16〜18時間後に開腹し、腹腔内温出液を採
取し、次いで10mMリン酸緩衝液(pH7,4)を含
む生理食塩水で2回腹腔内を洗浄した。得られた浸出液
と洗浄液を集め、150Xgで5分間遠心し、沈渣に0
.2%食塩水を加え、低張処理をして混入した赤血球を
溶血させた。これに1.6%食塩水を加えて等張に戻し
てから同様に遠心し、5(leM Repes緩衝液(
pH8,0)に懸濁後、超音波処理(Bransons
onirier、 model 185)を行った6
1G、0OOX gで10分間遠心し、その上清をさら
に105.OOOXgで60分間遠心分離し、得られた
上清を5−リポキシゲナーゼ画分とし、使用まで一70
℃にて凍結保存した。1/101 (I
A 2% casein solution (O++ 1/100 g body weight) was injected intraperitoneally, and 16-18 hours later, the abdomen was opened and the intraperitoneal exudate was collected, followed by saline containing 10 mM phosphate buffer (pH 7,4). The intraperitoneal cavity was lavaged twice. The obtained leachate and washing solution were collected, centrifuged at 150Xg for 5 minutes, and the sediment was
.. 2% saline was added and hypotonic treatment was performed to hemolyze the contaminated red blood cells. Add 1.6% saline to make it isotonic, centrifuge in the same way, and add 5 (leM Repes buffer).
After suspending in pH 8, 0), ultrasonication (Bransons
onirier, model 185)6
Centrifuge at 1G, 0OOX g for 10 minutes, and the supernatant is further centrifuged at 105. Centrifugation was carried out for 60 minutes at OOOXg, the resulting supernatant was used as the 5-lipoxygenase fraction, and it was kept for 170 minutes until use.
It was stored frozen at ℃.
反応液は、50mM Tris−塩酸緩衝液(pH7,
3)中に、5−リポキシゲナーゼ画分(0,5mg蛋白
)、3.4JJM (1−ロC〕アラキドン酸(40n
Ci、^sershamInternational)
、■曽輩塩化カルシウム、2mMのATP及び1 mM
グルタチオンを含み、全量を0.2mMとした。ジメチ
ルスルホキシドに溶解した被検化合物と上清画分を30
℃、2分間ブレインキュベーションした後、14C−ア
ラキドン酸を添加し、30℃、3分間インキュベーショ
ンした。0.4 Mクエン酸溶液20μeを加えて゛反
応を停止させ、反応生成物をエチルエーテルIs+にて
抽出した後、無水硫酸ナトリウム0.5 gを混和し軽
く遠心した。その上清0.6mMを別の試験管に移し、
乾固後、りaロホルムーメタノール(2: l ) 5
0u(11,:III解L、シリカゲルプレート(Th
atman、 LKsDF)にスポットした。プレート
には予め標準品のアラキドン酸、プロスタグランジンB
2.5−及び12− HE T Eをマーカーとしてス
ポットした。エチルエーテル石油エーテル−酢酸(85
:Is:0.1)の展開溶媒を用いて薄層クロマトを行
い、リニア・アナライザー(Berthold、 mo
del LB282)により5−HETE生成量を求め
た。The reaction solution was 50mM Tris-HCl buffer (pH 7,
3), 5-lipoxygenase fraction (0.5 mg protein), 3.4 JJM (1-ROC) arachidonic acid (40 n
Ci, ^sersham International)
, ■ Calcium chloride, 2mM ATP and 1mM
Contains glutathione, with a total amount of 0.2mM. The test compound dissolved in dimethyl sulfoxide and the supernatant fraction were
After incubation at 30°C for 2 minutes, 14C-arachidonic acid was added and incubated at 30°C for 3 minutes. The reaction was stopped by adding 20 μe of a 0.4 M citric acid solution, and the reaction product was extracted with ethyl ether Is+, followed by mixing with 0.5 g of anhydrous sodium sulfate and centrifuging briefly. Transfer 0.6mM of the supernatant to another test tube,
After drying, lyoform-methanol (2: l) 5
0u(11,:III solution L, silica gel plate (Th
atman, LKsDF). Standard products arachidonic acid and prostaglandin B were added to the plate in advance.
2.5- and 12-HETE were spotted as markers. Ethyl ether petroleum ether-acetic acid (85
Thin layer chromatography was performed using a developing solvent of :Is:0.1) and a linear analyzer (Berthold, mo
del LB282) to determine the amount of 5-HETE produced.
級1−
被検化合物の5−リポキシゲナーゼ阻害作用を5−HE
TE産生に対する50%抑制濃度(IC1゜。Class 1 - The 5-lipoxygenase inhibitory effect of the test compound is evaluated by 5-HE
50% inhibitory concentration (IC1°) on TE production.
μM)で求め、結果を第1表にまとめた。μM) and the results are summarized in Table 1.
第 1 表
被検化合物 5−リポキシゲナーゼ阻害能IC5o
(μM)
化合物(31) 0.2化合物(3
2) 0.05BW755G
2.5カフエー酸 75
第1表から明らかなように、本発明の化合物はいずれも
対照薬のBW755C,カフェー酸に比べ顕著に優れた
5−リポキシゲナーゼ作用阻害活性を示した。Table 1 Test compound 5-lipoxygenase inhibition ability IC5o
(μM) Compound (31) 0.2 Compound (3
2) 0.05BW755G
2.5 Caffeic acid 75 As is clear from Table 1, all the compounds of the present invention exhibited significantly superior 5-lipoxygenase action inhibitory activity compared to the control drug BW755C and caffeic acid.
試験例2
抗ヒスタミン作用
試験
本発明化合物の抗ヒスタミン作用をファン・ロッサムの
方法〔^rch、 Int、 Pharmacodyn
Ther、。Test Example 2 Antihistamine Effect Test The antihistamine effect of the compound of the present invention was evaluated by van Rossum's method [^rch, Int, Pharmacodyn.
Ther.
第143巻、第299頁(1963年)参照〕により行
った。すなわち、常法により雄性モルモット回腸標本を
作成し、空気を通した37℃のタイロード液を満たした
マグヌス管に懸垂し、ヒスタミンによる収縮を累積的に
等張性ヘーベルを介して記録した。143, p. 299 (1963)]. That is, a male guinea pig ileum specimen was prepared by a conventional method, suspended in a Magnus tube filled with Tyrode's solution at 37° C. through which air was passed, and contractions caused by histamine were cumulatively recorded via an isotonic Hebel tube.
被検化合物を試験3分館にタイロード液に添加し、競合
的拮抗作用及び非競合的拮抗作用をpAt及びpD’*
として求めた。The test compound was added to Tyrode's solution in the third test library, and competitive and non-competitive antagonism was determined by pAt and pD'*.
I asked for it as.
被検化合物のI) A を及びpD’*を求めた結果を
第2表にまとめた。The results of determining I) A and pD'* of the test compounds are summarized in Table 2.
第 2 表
試験例3
脂質過酸化防止作用
試験
本発明化合物の脂質過酸化防止作用を島田及び支出の方
法(Biochi@、 Biophys、^cta、第
489巻、第163頁(1977年)参照〕により行っ
た。すなわち、体重200 g前後の雄性ラットを用い
、常法により肝ミクロゾーム懸濁液を調製し、これをア
スコルビン酸100μ菖及び硫酸第一鉄20μ輩の存在
下に、37℃で60分間インキュベーションした後、生
成したマロンジアルデヒドの量をチオバルビッール酸法
により測定した。被検化合物はインキュベーション前に
添加した。Table 2 Test Example 3 Lipid peroxidation inhibitory effect test The lipid peroxidant inhibitory effect of the compounds of the present invention was determined by the method of Shimada and Shimada (see Biochi@, Biophys, ^cta, Vol. 489, p. 163 (1977)). Specifically, using male rats weighing around 200 g, a liver microsome suspension was prepared by a conventional method, and this was incubated at 37°C for 60 minutes in the presence of 100 μl of ascorbic acid and 20 μl of ferrous sulfate. After incubation, the amount of malondialdehyde produced was measured by the thiobarbic acid method.The test compound was added before incubation.
組l
被検化合物の脂質過酸化防止作用を対照群のマロンジア
ルデヒド生成に対する50%抑制濃度(ICa*。Group 1 The lipid peroxidation inhibitory effect of the test compound was determined by the 50% inhibitory concentration (ICa*) against malondialdehyde production in the control group.
μM)で求め、結果を第3表にまとめた。μM) and the results are summarized in Table 3.
第 3 表
被検化合物
脂質過酸化防止作用
IC,。(μM)
化合物(5)
化合物(6)
化合物(13)
化合物(30)
化合物(31)
化合物(32)
化合物(33)
化合物(34)
化合物(36)
化合物(37)
化合物(44)
化合物(45)
化合物(46)
第3表から明らかなように、本発明の化合物は優れた脂
質過酸化防止作用を示した。Table 3 Test compound lipid peroxidation inhibitory effect IC. (μM) Compound (5) Compound (6) Compound (13) Compound (30) Compound (31) Compound (32) Compound (33) Compound (34) Compound (36) Compound (37) Compound (44) Compound (45 ) Compound (46) As is clear from Table 3, the compound of the present invention exhibited excellent lipid peroxidation inhibitory activity.
試験例4
鎮痛作用
攻」
ヘングーショット(Henderghot)らの方法〔
J。Test Example 4 Analgesic effect method by Henderghot et al.
J.
Pharsaco1、 Expt1、 Therap1
、第125巻、第237頁(1957年)〕によった。Pharsaco1, Expt1, Therap1
, Vol. 125, p. 237 (1957)].
dd系雌性マウスを1群6匹とし、被検化合物100m
g/kgを経口投与した。1時間後、0.02%フェニ
ルキノン溶液を腹腔内投与し、その際に生じるストレッ
チ(5LreLch )症状の回数を20分間測定し、
対照群との間で有意性を検詞した。Groups of 6 female DD mice were treated with 100 m of the test compound.
g/kg was administered orally. After 1 hour, a 0.02% phenylquinone solution was administered intraperitoneally, and the number of stretching (5LreLch) symptoms that occurred at that time was measured for 20 minutes.
Significance was determined between the control group and the control group.
結果
対照群に対する抑制率(%)を求めたところ、化合物(
16)は48%の抑制率を示した。Results When we calculated the inhibition rate (%) against the control group, we found that the compound (
16) showed an inhibition rate of 48%.
このように本発明の3.4−ジヒドロ−2H−ベンゾピ
ラン誘導体(+−1)はヒトをはじめとするウマ、ウシ
、ブタ、イヌ、マウス、ラット、モルモット等の動物に
対して顕著な5−リポキシゲナーゼ作用阻害活性、抗ヒ
スタミン作用、脂質過酸化防止作用及び鎮痛作用を有す
る。As described above, the 3,4-dihydro-2H-benzopyran derivative (+-1) of the present invention has a significant 5- It has lipoxygenase inhibitory activity, antihistamine effect, lipid peroxidation prevention effect, and analgesic effect.
また本発明の3.4〜ジヒドロ−2H−ベンゾピラン誘
導体(I−1)は低毒性であり、例えば本発明の化合物
(45)の急性毒性値(LDso、 dd系雄性マウス
)は経口投与で> 1,000■g/kgであった。Furthermore, the 3.4-dihydro-2H-benzopyran derivative (I-1) of the present invention has low toxicity; for example, the acute toxicity value (LDso, DD male mouse) of the compound (45) of the present invention is > It was 1,000 g/kg.
以上、明らかにしたように、本発明の3.4−ジヒドロ
−2H−ベンゾピラン誘導体(1−1)はヒトをはじめ
とするウマ、ウシ、ブタ、イヌ、マウス、ラット、モル
モット等の動物の気管支喘息、アレルギー性疾患(アレ
ルギー性鼻炎など)、免疫性疾患(自己免疫不全症、感
染症など)、炎症性疾患(関節リウマチ、強直性を椎炎
など)、乾癬、脳血管障害、虚血性心疾患、血栓症、疼
痛などの各種疾患に対する治療薬として有用である。As clarified above, the 3,4-dihydro-2H-benzopyran derivative (1-1) of the present invention can be used in the bronchus of animals such as humans, horses, cows, pigs, dogs, mice, rats, and guinea pigs. Asthma, allergic diseases (allergic rhinitis, etc.), immune diseases (autoimmune deficiencies, infectious diseases, etc.), inflammatory diseases (rheumatoid arthritis, ankylosing spondylitis, etc.), psoriasis, cerebrovascular disorders, ischemic heart It is useful as a therapeutic agent for various diseases such as disease, thrombosis, and pain.
3.4−ジヒドロ−2H−ベンゾピラン誘導体(1−1
)の投与量は疾病、患者の重篤度、薬物に対する忍容性
などにより異なるが、通常成人!臼あたり5〜2000
mg、好ましくは50〜600慣gの量であり、これを
1回又は分割j、て投与するのがよい。投与に際しては
投与ルートに適した任意の形態をとることができる。3.4-dihydro-2H-benzopyran derivative (1-1
) dosage varies depending on the disease, patient severity, drug tolerance, etc., but is usually for adults! 5-2000 per mortar
mg, preferably 50 to 600 mg, which may be administered once or in divided doses. For administration, any form suitable for the administration route can be taken.
3.4−ジヒドロ−2H−ベンゾビラン誘導体(1−1
)は任意慣用の製剤方法を用いて投与用にFi製するこ
とができる。従って、本発明は少なくとも1種の34−
ジヒドロ−2H−ベンゾビラン誘導体(+−1)を含有
する医薬組成物をも包含するものである。このような組
成物は任意所要の製薬用担体、賦形剤等の医薬上許容さ
れる添加剤等を使用して慣用の手段によって調製される
。3.4-dihydro-2H-benzobilane derivative (1-1
) can be prepared for administration using any conventional formulation method. Therefore, the present invention provides at least one 34-
It also encompasses pharmaceutical compositions containing dihydro-2H-benzobilane derivatives (+-1). Such compositions are prepared by conventional means using any required pharmaceutical carriers, excipients, and other pharmaceutically acceptable additives.
この組成物が経口用製剤である場合には、該製剤は消化
管からの吸収に好適な形態で提供されるのが望ましい。When the composition is an oral formulation, it is desirable that the formulation be provided in a form suitable for absorption from the gastrointestinal tract.
経口投与の錠剤及びカプセルは単位量投与形態であり、
結合剤、例えばシロップ、アラビアゴム、ゼラチン、ソ
ルビット、トラカント、ポリビニルピロリドンなど;賦
形薬、例えば乳糖、とうもろこし澱粉、りん酸カルシウ
ム、ソルビット、グリノンなど:潤滑剤、例えばステア
リン酸マグネシウム、タルク、ポリエチレングリコール
、シリカなど:崩壊剤、例えば馬鈴11jl粉など;又
は許容し得る湿潤剤、例えばラウリル硫酸ナトリウムな
どのような慣用の賦形剤を含有していてもよい。錠剤は
当業界において周知の方法でコーティングしてもよい。Tablets and capsules for oral administration are unit dose forms;
Binders, such as syrup, acacia, gelatin, sorbitol, tracanth, polyvinylpyrrolidone, etc.; Excipients, such as lactose, corn starch, calcium phosphate, sorbitol, glinone, etc.; Lubricants, such as magnesium stearate, talc, polyethylene glycol. , silica, etc.; or conventional excipients, such as disintegrants, such as potato 11jl flour; or acceptable wetting agents, such as sodium lauryl sulfate. Tablets may be coated by methods well known in the art.
経口用液体製剤は水性又は油性懸濁剤、溶液、シロップ
、エリキシル剤、その他であってもよく、あるいは使用
する前に水又は他の適当なビヒクルで再溶解させる乾燥
生成物であってもよい。このような液体製剤は普通に用
いられる添加剤、例えば懸濁化剤、例えばソルビットシ
ロップ、メチルセルロース、グルコース/糖シロップ、
ゼラチン、ヒドロキシエチルセルロース、カルボキシメ
チルセルロース、ステアリン酸アルミニウムゲル、水素
化食用脂など;乳化剤、例えばレシチン、モノオレイン
酸ソルビタン、アラビアゴムなど:非水性ビヒクル、例
えばアーモンド油、分別ココナツト油、油性エステル、
プロピレングリコール、エチルアルコールなど;防腐剤
、例えばp−ヒドロキシ安息香酸メチル、p−ヒドロキ
シ安息香酸プロピル、ソルビン酸などを含有してもよい
。Oral liquid preparations may be aqueous or oily suspensions, solutions, syrups, elixirs, etc., or they may be dry products that are redissolved in water or other suitable vehicle before use. . Such liquid formulations may contain commonly used excipients such as suspending agents such as sorbitol syrup, methylcellulose, glucose/sugar syrups,
Gelatin, hydroxyethylcellulose, carboxymethylcellulose, aluminum stearate gel, hydrogenated edible fat, etc.; emulsifiers, such as lecithin, sorbitan monooleate, gum arabic, etc.; non-aqueous vehicles, such as almond oil, fractionated coconut oil, oily esters,
Propylene glycol, ethyl alcohol, etc.; preservatives such as methyl p-hydroxybenzoate, propyl p-hydroxybenzoate, sorbic acid, etc. may be contained.
また注射剤を調製する場合には、3.4−ジヒドロ−2
H−ベンゾピラン誘導体(1−1)に必要によりpH!
II整削、緩衝剤、安定化剤、保存剤、可溶化剤などを
添加し、常法により皮下、筋肉内、静脈内注射剤とする
。In addition, when preparing injections, 3,4-dihydro-2
pH! H-benzopyran derivative (1-1) if necessary!
After adding buffering agents, stabilizing agents, preservatives, solubilizing agents, etc., it is prepared as a subcutaneous, intramuscular, or intravenous injection by a conventional method.
(実施例)
以下に、本発明を実施例により具体的(こ説明するが、
本発明はこれらの実施例1こより限定されるものではな
い。(Example) Hereinafter, the present invention will be explained in more detail with reference to Examples.
The present invention is not limited to these first embodiments.
なお、以下の記載においてCDCl3 iよCDC1,
を、da−DMSOはda−DMSOを、CD30D
fよCD、ODをC20+より、Oを意味する。In addition, in the following description, CDCl3i and CDC1,
, da-DMSO is da-DMSO, CD30D
f means CD, OD from C20+, meaning O.
実施例1
水素ナトリウム水溶液で順次洗浄し、無水硫酸ナトリウ
ムで乾燥したのち、これより低沸点化合物を減圧下に留
去した。残渣をシリカゲルカラムクロマトグラフィーで
精製することにより、6−ベンジルオキシ−3,4−ジ
ヒドロ−2,5,7,8−テトラメチル−2H−ベンゾ
ビラン−2−イルアセトアミド(化合物1)を得た。生
成物の収率及び物性値を第4表に示した。Example 1 After sequentially washing with an aqueous sodium hydrogen solution and drying over anhydrous sodium sulfate, low-boiling compounds were distilled off under reduced pressure. The residue was purified by silica gel column chromatography to obtain 6-benzyloxy-3,4-dihydro-2,5,7,8-tetramethyl-2H-benzobilan-2-ylacetamide (Compound 1). The yield and physical properties of the product are shown in Table 4.
実施例2〜4
乾燥したベンゼン150m1に、6−ベンジルオキシ−
3,4−ジヒドロ−2,5,7,8−テトラメチル−2
H−ベンゾビラン−2−イル酢酸2Q、Og(56,5
asol)、塩化チオニル8.51及びジメチルホルム
アミド50μlからなる混合溶液を2時間、加熱還流し
た。冷却後、低沸点物を減圧下に留去した。これを、ア
ンモニアを飽和させた塩化メチレン20Q+*lを一7
8℃に冷却したものにゆっくり滴下し、滴下終了後、室
温で終夜撹拌した。反応液を水ζこあζすでエーテルで
抽出した。エーテル層を希塩酸及び飽和炭酸実施例1に
おいてアンモニアの代わりにセチルアミン、2−モルフ
ォリノエチルアミン又は1フエニルピペラジンをそれぞ
れlI3mmol用いた以外は同様にして反応及び分離
操作を行なうことにより、それぞれ対応するN−セチル
−6−ベンジルオキシ−3,4−ジヒドロ−2,5,7
,8−テトラメチル−2H−ベンゾビラン−2−イルア
セトアミド(化合物2)、N−(2−モルフォリノエチ
ル)−6−ペンジルオキンー3.4− ジヒドロ−2
,5,7゜8−テトラメチル−2H−ベンゾビラン−2
−イルアセトアミド(化合物3)及びN−(4−フェニ
ルピペラジン−1−イル)−6−ペンジルオキノー3.
4−ジヒドロ−2,5,7,8−テトラメチル−2H−
ベンゾビラン−2−イルアセトアミド(化合物4)を得
た。生成物の収率及び物性値を第4表に示した。Examples 2-4 6-benzyloxy-
3,4-dihydro-2,5,7,8-tetramethyl-2
H-benzobylan-2-yl acetic acid 2Q, Og (56,5
A mixed solution consisting of 8.51 l of thionyl chloride and 50 μl of dimethylformamide was heated under reflux for 2 hours. After cooling, low boilers were distilled off under reduced pressure. Add this to 17Q+*l of methylene chloride saturated with ammonia.
The mixture was slowly added dropwise to the mixture cooled to 8°C, and after the addition was completed, the mixture was stirred at room temperature overnight. The reaction solution was extracted with water and ether. The ether layer was treated with dilute hydrochloric acid and saturated carbonic acid.The reaction and separation operations were carried out in the same manner as in Example 1 except that 3 mmol of cetylamine, 2-morpholinoethylamine, or 1-phenylpiperazine was used in place of ammonia. -cetyl-6-benzyloxy-3,4-dihydro-2,5,7
, 8-tetramethyl-2H-benzobilan-2-ylacetamide (compound 2), N-(2-morpholinoethyl)-6-pendyluoquine-3.4-dihydro-2
,5,7゜8-tetramethyl-2H-benzobilane-2
-ylacetamide (compound 3) and N-(4-phenylpiperazin-1-yl)-6-penzyloquino3.
4-dihydro-2,5,7,8-tetramethyl-2H-
Benzobilan-2-ylacetamide (compound 4) was obtained. The yield and physical properties of the product are shown in Table 4.
以下余白
第 4
表
57.5
49.6
97.2
91.1
1.33(s、3FI)、 [M]”3531
.77〜2.27(m、1lH)。Margin below 4 Table 57.5 49.6 97.2 91.1 1.33 (s, 3FI), [M]”3531
.. 77-2.27 (m, 11H).
2.40〜2.75(m、4H)。2.40-2.75 (m, 4H).
4.67(s、2H)。4.67 (s, 2H).
5.77(brs、IH)。5.77 (brs, IH).
6.22(brs、III)。6.22 (brs, III).
7.27〜7.58(仇、5H)
1.05〜1.63(−,33H)、 [M]”57
82.03〜2.27(a、911)。7.27-7.58 (enemy, 5H) 1.05-1.63 (-, 33H), [M]"57
82.03-2.27 (a, 911).
2.43〜2.72(−,4H)。2.43-2.72 (-, 4H).
3.07〜3.35(m、2)1)。3.07-3.35 (m, 2) 1).
4.67(s、2H)。4.67 (s, 2H).
6.07〜6.37(@、lH)。6.07-6.37 (@, lH).
7.27〜7.57(g+、5H) 1.32(s、3H)。7.27-7.57 (g+, 5H) 1.32 (s, 3H).
1.67〜2.77(a、21H)。1.67-2.77 (a, 21H).
4.67(8,2H)。4.67 (8,2H).
6.40〜6.83(陶、IH)。6.40-6.83 (ceramic, IH).
7.17〜7.67(a、58) 1.32(s、3B)、 1.60〜2.13(a、IIH)。7.17-7.67 (a, 58) 1.32 (s, 3B), 1.60-2.13 (a, IIH).
2.22〜2.76(*、4H)。2.22-2.76 (*, 4H).
2.93〜3.20(m、4H)。2.93-3.20 (m, 4H).
3.49〜3,86(m、4)1) 3.55〜3.90(brs、IH)。3.49-3,86 (m, 4) 1) 3.55-3.90 (brs, IH).
4.66(s、2H)。4.66 (s, 2H).
6.80〜7.67(m、l0H)
[M]”499
[M]”46?
実施例5
実施例1において得られた6−ベンジルオキシ−3,4
−ジヒドロ−2,5,7,8−テトラメチル−2Hベン
ゾピラン−2−イルアセトアミド11.5g(32,6
s+mol)をエタノール100+alに溶解し、これ
に1N−塩酸30m1及びPd/C(5%) 2.5g
を加えて水素雰囲気下、室温で終夜撹拌した。Pd/C
を濾過し、濾液より低沸点物を減圧下に留去することに
より3.4−ジヒドロ−6−ヒドロキシ−2,5,7,
8−テトラメチル−2H−ベンゾビラン−2−イルアセ
トアミド(化合物5)を得た。生成物の収率及び物性値
を第5表に示した。6.80~7.67 (m, l0H) [M]”499 [M]”46? Example 5 6-benzyloxy-3,4 obtained in Example 1
-dihydro-2,5,7,8-tetramethyl-2H benzopyran-2-ylacetamide 11.5 g (32,6
s+mol) in 100+al of ethanol, and to this was added 30ml of 1N-hydrochloric acid and 2.5g of Pd/C (5%).
was added thereto, and the mixture was stirred at room temperature overnight under a hydrogen atmosphere. Pd/C
3.4-dihydro-6-hydroxy-2,5,7,
8-tetramethyl-2H-benzobilan-2-ylacetamide (compound 5) was obtained. The yield and physical properties of the product are shown in Table 5.
実施例6〜8
実施例5において6−ベンジルオキシ−34−ノヒドロ
ー2.5,7.8−テトラメチル−2H−ベンゾビラン
−2−イルアセトアミドの代わりに実施例2〜4におい
て合成したN−セチル−6−ベンジルオキシ−3,4−
ジヒドロ−2,5,7,8−テトラメチル−2H−ベン
ゾビラン−2−イルアセトアミド、N−(2−モルフォ
リノエチル)−6−ベンジルオキシ−3,4−ジヒドロ
−2,5,7,8−テトラメチル−211−ベンゾビラ
ン−2−イルアセトアミド又は(4−フェニルピペラジ
ン−1−イル)−6−ベンジルオキシ−3,4−ジヒド
ロ−2,5,フ、8−テトラメチル−2H−ベンゾビラ
ン−2−イルアセトアミドをそれぞれ用いた以外は同様
にして反応及び分離操作を行なうことによりそれぞれ対
応するN−セチル−3,4−ジヒドロ−6−ヒドロキシ
2.5.7.8−テトラメチル−2F+−ベンゾビラン
−2=イルアセトアミド(化合物6)、N−(2−フル
7オリノエチル)−3,4−ジヒドロ−6−ヒドロキシ
−2,5,7,8−テトラメチル−2H−ベンゾビラン
−2−イルアセトアミド(化合物7)及びN−(4−フ
ェニルピペラジン−I−イル)−3,4−ジヒドロ−6
−ヒドロキシ−2,5,7,8−テトラメチル−2■−
ベンゾビラン−2−イルアセトアミド(化合物8)を得
た。生成物の収率及び物性値を第5表に示した。Examples 6-8 N-cetyl synthesized in Examples 2-4 in place of 6-benzyloxy-34-nohydro-2.5,7.8-tetramethyl-2H-benzobylan-2-ylacetamide in Example 5 -6-benzyloxy-3,4-
Dihydro-2,5,7,8-tetramethyl-2H-benzobilan-2-ylacetamide, N-(2-morpholinoethyl)-6-benzyloxy-3,4-dihydro-2,5,7,8 -Tetramethyl-211-benzobylan-2-ylacetamide or (4-phenylpiperazin-1-yl)-6-benzyloxy-3,4-dihydro-2,5,8-tetramethyl-2H-benzobilane- The corresponding N-cetyl-3,4-dihydro-6-hydroxy 2.5.7.8-tetramethyl-2F+- was obtained by performing the reaction and separation in the same manner except that 2-ylacetamide was used. Benzobilan-2-ylacetamide (compound 6), N-(2-fur7-olinoethyl)-3,4-dihydro-6-hydroxy-2,5,7,8-tetramethyl-2H-benzobilan-2-ylacetamide (Compound 7) and N-(4-phenylpiperazin-I-yl)-3,4-dihydro-6
-Hydroxy-2,5,7,8-tetramethyl-2■-
Benzobilan-2-ylacetamide (compound 8) was obtained. The yield and physical properties of the product are shown in Table 5.
第 5 表
実施例 生成物
番号 化合物 収率 ’ H−NMRスペクトル
FD質量5 5 89.1
17.2
[M] +263
1.33(s、3H)。Table 5 Examples Product number Compound Yield 'H-NMR spectrum
FD mass 5 5 89.1 17.2 [M] +263 1.33 (s, 3H).
1.70〜2.77(s、40)。1.70-2.77 (s, 40).
4.30(brs、3H)
0.87〜1.47(會、33H)、 [M]+4
881.90〜2.13(m、9H)。4.30 (brs, 3H) 0.87-1.47 (kai, 33H), [M]+4
881.90-2.13 (m, 9H).
2.30〜2.73(門、4H)。2.30-2.73 (gate, 4H).
3.17(brs、IH)。3.17 (brs, IH).
5.07(brs、IH) 1.23(s、3)1)。5.07 (brs, IH) 1.23 (s, 3) 1).
1.37〜2.80(a、21H)。1.37-2.80 (a, 21H).
2.93〜3.73(g+、6H)。2.93-3.73 (g+, 6H).
4.27(brs、IH)。4.27 (brs, IH).
7.87〜8.00(brs、 IH)1.32(s、
3H)。7.87-8.00 (brs, IH) 1.32 (s,
3H).
1.60〜2.13(a、11H)。1.60-2.13 (a, 11H).
2.22〜2.76(−,41)。2.22-2.76(-,41).
2.93〜3.20(m、4H)。2.93-3.20 (m, 4H).
3.49〜3.86(s、4H)。3.49-3.86 (s, 4H).
3.55〜3.90(brs、IH)。3.55-3.90 (brs, IH).
6.80〜7.40(a、5H)
[i1]”377
[11]”409
実施例9
キシレン200m1と3.4−ジヒドロ−6−ヒドロキ
シ−2,5,7,8−テトラメチル−2H−ベンゾビラ
ン−2−イルカルボン酸1G、Og (39,7sao
l)及びエタノールアミン大過剰からなる溶液を7時間
加熱還流した。冷却後、得られた反応液より低沸点物を
減圧下に留去した。得られた粗結晶をベンゼン及びメタ
ノールにて再結晶することにより、下記の物性を有する
N−(2−ヒドロキシエチル)−3,4−ジヒドロ−6
−ヒドロキシ−2,5,7,8−テトラメチル−2H−
ベンゾビラン−2−イルカルボキサミド(化合物9)8
.49を得た。収率71.7%。6.80-7.40 (a, 5H) [i1]"377 [11]"409 Example 9 200 ml of xylene and 3,4-dihydro-6-hydroxy-2,5,7,8-tetramethyl-2H -benzobilan-2-ylcarboxylic acid 1G, Og (39,7sao
A solution consisting of 1) and a large excess of ethanolamine was heated to reflux for 7 hours. After cooling, low-boiling substances were distilled off from the resulting reaction solution under reduced pressure. By recrystallizing the obtained crude crystals from benzene and methanol, N-(2-hydroxyethyl)-3,4-dihydro-6 having the following physical properties was obtained.
-hydroxy-2,5,7,8-tetramethyl-2H-
Benzobilan-2-ylcarboxamide (compound 9) 8
.. I got 49. Yield 71.7%.
FD質量スペクトル: [M]”= 293’H−NM
Rスペクトル(90klHz) : 1.00〜2.8
7(m。FD mass spectrum: [M]"=293'H-NM
R spectrum (90klHz): 1.00-2.8
7 (m.
4H)、 1.47(g、3H)、 2.00(s、3
H)、2.07(s、6H)。4H), 1.47 (g, 3H), 2.00 (s, 3
H), 2.07 (s, 6H).
2.33〜2.87(m、4H)、 3.53(t、
J=4.5Hz、2H)。2.33-2.87 (m, 4H), 3.53 (t,
J=4.5Hz, 2H).
6.20(brs、3H)
実施例10
(式中、DCCは1.3−ジシクロへキシルカルボジイ
ミドを表わす)
クロロホルム50−1.3.4−ジヒドロ−6−ヒドロ
キシ−2,5,7,8−テトラメチル−2H−ベンゾビ
ラン−2−イルプロピオン酸3.0g (10,8a鴫
o1)及び4− (2,3,4−トリメトキシベンジル
)ピペラジン2.7g (10,8gmol)からなる
混合溶液を窒素気流下0℃に冷却し、これに1.3−ジ
クロロへキシルカルボジイミド2.25g (10,9
m5ol)を加えた。6.20 (brs, 3H) Example 10 (wherein, DCC represents 1,3-dicyclohexylcarbodiimide) Chloroform 50-1.3.4-dihydro-6-hydroxy-2,5,7,8 -A mixed solution consisting of 3.0 g (10,8a) of -tetramethyl-2H-benzobyran-2-ylpropionic acid and 2.7 g (10,8 gmol) of 4-(2,3,4-trimethoxybenzyl)piperazine was cooled to 0°C under a nitrogen stream, and 2.25 g of 1,3-dichlorohexylcarbodiimide (10,9
m5ol) was added.
0℃で3時間撹拌したのち室温まで昇温した。反応液に
エーテルを加えて濾過し、濾液を2回水洗し、無水硫酸
ナトリウムで乾燥したのち、これより低沸点物を減圧下
に留去した。得られた残渣をシリカゲルカラムクロマト
グラフィーにて精製することにより、下記の物性を有す
る3、4−ジヒドロ−6〜ヒドロキシ−2,5,7,8
−テトラメチル−2−[2−(4−(2,3,4−)リ
メトキンベンジル)ピペラジン−1−イルカルボニル〕
エチル]−2tl−ベンゾビラン(化合物10) 2.
1 gを得た。収率37.0%。After stirring at 0°C for 3 hours, the temperature was raised to room temperature. Ether was added to the reaction mixture and filtered. The filtrate was washed twice with water and dried over anhydrous sodium sulfate, and then low-boiling substances were distilled off under reduced pressure. The obtained residue was purified by silica gel column chromatography to obtain 3,4-dihydro-6-hydroxy-2,5,7,8 having the following physical properties.
-tetramethyl-2-[2-(4-(2,3,4-)rimethquinbenzyl)piperazin-1-ylcarbonyl]
ethyl]-2tl-benzobilane (compound 10) 2.
1 g was obtained. Yield 37.0%.
FD質量スペクトル: Cl!]”=52y’H−NM
Rスペクトル(90旧(z) : 1.17(s、3H
)。FD mass spectrum: Cl! ]"=52y'H-NM
R spectrum (90 old (z): 1.17 (s, 3H
).
1.50〜2.87(s、21H)、 3.13〜3.
66(m、6H)。1.50-2.87 (s, 21H), 3.13-3.
66 (m, 6H).
3.83(s、9H)、 4.30(brs、I)l)
、 6.70(dd、J=2.857.50Hz、21
f)
実施例1!
乾燥したベンゼンIQOm1、 8−アセトキノ−3
4−ジヒドロ−2,5,7,8−テトラメチル−2H−
ベンゾビラン−2〜イルカルボン酸5.Og(17,7
ssol)、ジメチルホルムアミド20μl及び塩化チ
オニル1.sol (2+1.6−sol)からなる混
合溶液を2時間加熱還流した。冷却後、低沸点物を減圧
下に留去した。3.83 (s, 9H), 4.30 (brs, I)l)
, 6.70(dd, J=2.857.50Hz, 21
f) Example 1! Dried benzene IQOm1, 8-acetoquino-3
4-dihydro-2,5,7,8-tetramethyl-2H-
Benzobilan-2-ylcarboxylic acid 5. Og(17,7
ssol), 20 μl dimethylformamide and thionyl chloride 1. A mixed solution consisting of sol (2+1.6-sol) was heated under reflux for 2 hours. After cooling, low boilers were distilled off under reduced pressure.
これを、1.2−ジクロロエタン100m1、l−フェ
ニルピペラジン2.75g (17,0農mol)及び
ピリジン1.24g (17,0ssol)からなる混
合溶液を0℃に冷却したものにゆっくり滴下し、室温で
終夜撹拌した。反応混合物を水にあけ、塩化メチレンで
抽出した。有機層を水、希塩酸、飽和炭酸水素ナトリウ
ム水溶液で順次洗浄し、無水硫酸ナトリウムで乾燥した
のち、低沸点物を減圧下に留去した。得られた残渣をシ
リカゲルカラムクロマトグラフィーで精製することによ
り、6−アセトキシ−34−ジヒドロ−2,5,7,8
−テトラメチル−2−[(4−フェニルピペラジン−1
−イル)カルボニル〕ベンゾピラン(化合物11)を6
.9g得た。生成物の収率及び物性値を第6表に示した
。This was slowly added dropwise to a mixed solution of 100 ml of 1,2-dichloroethane, 2.75 g (17,0 mol) of l-phenylpiperazine, and 1.24 g (17,0 ssol) of pyridine cooled to 0°C. Stirred at room temperature overnight. The reaction mixture was poured into water and extracted with methylene chloride. The organic layer was washed successively with water, diluted hydrochloric acid, and a saturated aqueous sodium bicarbonate solution, dried over anhydrous sodium sulfate, and then low-boiling substances were distilled off under reduced pressure. The obtained residue was purified by silica gel column chromatography to obtain 6-acetoxy-34-dihydro-2,5,7,8
-tetramethyl-2-[(4-phenylpiperazine-1
-yl)carbonyl]benzopyran (compound 11) 6
.. I got 9g. The yield and physical properties of the product are shown in Table 6.
実施例12
実施例11においてl−7エニルピベラジンの代わりに
2−モルフォリノエチルアミン2.48g(17,0s
sol )を用いた以外は同様にして反応及び分離操作
を行なうことによりN−(2−モルフォリノエチル)−
6〜アセトキシ−3,4−ジヒドロ〜2.5゜7.8−
テトラメチル−2H−ベンゾビラン−2−イルカルボキ
サミド(化合物12)をS、O、得た。生成物の収率及
び物性値は第6表に示した。Example 12 In Example 11, 2.48 g of 2-morpholinoethylamine (17,0 s
N-(2-morpholinoethyl)-
6-acetoxy-3,4-dihydro-2.5゜7.8-
Tetramethyl-2H-benzobylan-2-ylcarboxamide (compound 12) was obtained as S,O. The yield and physical properties of the product are shown in Table 6.
第 6 表
11 11 92.1 [
M]+43612 12 69.8
[M]”401実施例13
エタノール100m1と実施例11において合成した6
−アセトキシ−3,4−ジヒドロ−2,5,7,8−テ
トラメチル−2−((4−フェニルピベラノンーl−イ
ル)カルボニル〕ベンゾピラン6.9g (15,8m
5ol)からなる混合溶液に水酸化カリウム1.8g(
31,7gmol)を加えて室温で終夜撹拌した。反応
液を水にあけて希塩酸で中和したのち、酢酸エチルで抽
出し、有機層を水洗して無水硫酸ナトリウムで乾燥した
。低沸点物を減圧下で留去したのち残渣をエタノールで
再結晶することにより、下記の物性を有する3、4−ジ
ヒドロ−6−ヒドロキソ−2,5,7,8−テトラメチ
ル−2−CC4−フェニルピペラジン−1−イル)カル
ボニル〕ベンゾビラン(化合物13)を得た。生成物の
収率及び物性値を第7表に示した。Table 6 11 11 92.1 [
M]+43612 12 69.8
[M]”401 Example 13 6 synthesized in Example 11 with 100 ml of ethanol
6.9 g (15.8 m
1.8 g of potassium hydroxide (
31.7 gmol) was added thereto, and the mixture was stirred at room temperature overnight. The reaction solution was poured into water, neutralized with dilute hydrochloric acid, extracted with ethyl acetate, and the organic layer was washed with water and dried over anhydrous sodium sulfate. After distilling off the low boiling point substances under reduced pressure, the residue was recrystallized with ethanol to obtain 3,4-dihydro-6-hydroxo-2,5,7,8-tetramethyl-2-CC4 having the following physical properties. -phenylpiperazin-1-yl)carbonyl]benzobilane (Compound 13) was obtained. The yield and physical properties of the product are shown in Table 7.
実施例14
実施例13において、6−アセトキシ−34−ジヒドロ
−2,5,7,g−テトラメチル−2−C(4−フェニ
ルピペラジン−1−イル)カルボニル〕ベンゾビランの
代わりに実施例12において合成したN−(2−モルフ
ォリノエチル)−6−アセトキノ3.4−ジヒドロ−2
,5,7,8−テトラメチル−2H−ベンゾビラン−2
−イルカルボキサミドを用いた以外は同様にして反応及
び後処理を行なうことにより、下記の物性を有するN−
(2−モルフォリノエチル)−3,4−ジヒドロ−6−
ヒドロキン−2,5,7,8−テトラメチル−2H−ベ
ンゾピラン2−イルカルボキサミド(化合物14)を得
た。生成物の収率及び物性値を第7表に示した。Example 14 In Example 13, in place of 6-acetoxy-34-dihydro-2,5,7,g-tetramethyl-2-C(4-phenylpiperazin-1-yl)carbonyl]benzobilane in Example 12 Synthesized N-(2-morpholinoethyl)-6-acetoquino3,4-dihydro-2
,5,7,8-tetramethyl-2H-benzobilane-2
By performing the reaction and post-treatment in the same manner except that -yl carboxamide was used, N-
(2-morpholinoethyl)-3,4-dihydro-6-
Hydroquine-2,5,7,8-tetramethyl-2H-benzopyran-2-ylcarboxamide (compound 14) was obtained. The yield and physical properties of the product are shown in Table 7.
第 7 表 実施例15 76.2 12.0 1.46(s、3H) 1.83〜2.t3(s、6H)。Table 7 Example 15 76.2 12.0 1.46 (s, 3H) 1.83-2. t3(s, 6H).
2.18〜2.60(m、611) 2.78〜3.08(m、48)。2.18-2.60 (m, 611) 2.78-3.08 (m, 48).
3.50〜4.05(brs、1)I)。3.50-4.05 (brs, 1)I).
660〜7.31(s、5H) 143(s、311) 1.57〜2.67(+、19H)。660-7.31 (s, 5H) 143 (s, 311) 1.57-2.67 (+, 19H).
3、lθ〜3.40(m、2H) 3.50(L、J=5.0Hz、4)1)。3, lθ~3.40 (m, 2H) 3.50 (L, J=5.0Hz, 4)1).
4 、23(brs 、 IH) 。4, 23 (brs, IH).
6.97(brs、 IH)
[M]”395
[M]+362
乾燥した1、2−ジクロロエタン50+s1、6−ベン
ジルオキシ−3,4−ジヒドロ−2,5,7,8−テト
ラメチル−2H−ベンゾビラン−2−イル酢酸8.86
g(25,0m5ol)、ジメチルホルムアミド50μ
m及び塩化チオニル3.5Lg (30園mol)から
なる混合溶液を2時間加熱還流した。冷却後、低沸点物
を減圧下に留去した。これを1.2−ジクロロエタン5
011で希釈し、1.2−ジクロロエタン501.3−
アミノピリジン2.8g (30++5ol)及びピリ
ジン1.98g (25gmol)からなる混合溶液を
0℃に冷却したものにゆっくりと滴下した。滴下終了後
、室温で終夜撹拌したのち、反応液を水にあけて塩化メ
チレンで抽出した。塩化メチレン層を水と飽和塩化ナト
リウム水溶液で順次洗浄し、無水硫酸ナトリウムで乾燥
したのち、低沸点物を減圧下に留去した。残渣をシリカ
ゲルカラムクロマトグラフィーにて精製することにより
、N−(3−ピリジル)−6−ベンジルオキシ−3,4
−ジヒドロ−2,5,フ、8−テトラメチル−2H−ベ
ンゾピラン−2−イルアセトアミド(化合物15)を9
.3g得た。生成物の収率及び物性値を第8表に示した
。6.97 (brs, IH) [M]”395 [M]+362 Dry 1,2-dichloroethane 50+s1,6-benzyloxy-3,4-dihydro-2,5,7,8-tetramethyl-2H- Benzobilan-2-yl acetic acid 8.86
g (25.0m5ol), dimethylformamide 50μ
A mixed solution consisting of 3.5 Lg (30 moles) of thionyl chloride and thionyl chloride was heated under reflux for 2 hours. After cooling, low boilers were distilled off under reduced pressure. Add this to 1,2-dichloroethane 5
Diluted with 011, 1,2-dichloroethane 501.3-
A mixed solution consisting of 2.8 g (30++5 ol) of aminopyridine and 1.98 g (25 gmol) of pyridine was slowly added dropwise to the mixture cooled to 0°C. After the dropwise addition was completed, the mixture was stirred at room temperature overnight, and then the reaction mixture was poured into water and extracted with methylene chloride. The methylene chloride layer was washed successively with water and a saturated aqueous sodium chloride solution, dried over anhydrous sodium sulfate, and then low-boiling substances were distilled off under reduced pressure. By purifying the residue using silica gel column chromatography, N-(3-pyridyl)-6-benzyloxy-3,4
-dihydro-2,5,ph,8-tetramethyl-2H-benzopyran-2-ylacetamide (compound 15) at 9
.. I got 3g. The yield and physical properties of the product are shown in Table 8.
実施例16〜30
実施例15において、3−アミノピリジンの代わりに第
5表に示したアミンを用いた以外は同様にして反応及び
分離操作を行なうことにより、それぞれ対応するアミド
化合物を得た。生成物の収率及び物性値を第8表に示し
た。Examples 16 to 30 Corresponding amide compounds were obtained by carrying out the reaction and separation operations in the same manner as in Example 15, except that the amines shown in Table 5 were used instead of 3-aminopyridine. The yield and physical properties of the product are shown in Table 8.
以下余白
実施例31
実施例15において合成したN−(3−ピリジル)−6
−ベンジルオキシ−3,4−ジヒドロ−2,5,7゜8
−テトラメチル−2H−ベンゾピラン−2−イルアセト
アミド9.3g (21,6s@ol)と乾燥した塩化
メチレン10(lslからなる混合溶液を窒素気流下、
0℃に冷却し、これに三塩化ホウ素の塩化メチレン溶液
(Imol/l)を47.2ml (47,2gmol
) i!!下した。Below are blank spaces Example 31 N-(3-pyridyl)-6 synthesized in Example 15
-benzyloxy-3,4-dihydro-2,5,7゜8
-Tetramethyl-2H-benzopyran-2-ylacetamide 9.3 g (21,6 s@ol) and dry methylene chloride 10 (lsl) were added to a mixed solution under a nitrogen stream.
Cool to 0°C, add 47.2 ml (47.2 gmol) of boron trichloride in methylene chloride solution (Imol/l)
)i! ! I put it down.
室温で30分撹拌したのち、反応液を飽和炭酸水素ナト
リウム水溶液にあけ、塩化メチレンで抽出した。有機層
を減圧下に留去した。残渣をシリカゲルカラムクロマト
グラフィーで精製することにより、下記の蝉性を有する
N−(3−ピリジル)−3,4−ジヒドロ−6−ヒドロ
キシ−2,5,7,8−テトラメチル−2H−ベンゾビ
ラン−2−イルアセトアミド(化合物31)を4.0g
得た。生成物の収率及び物性値を第9表に示した。After stirring at room temperature for 30 minutes, the reaction solution was poured into a saturated aqueous sodium bicarbonate solution and extracted with methylene chloride. The organic layer was distilled off under reduced pressure. By purifying the residue by silica gel column chromatography, N-(3-pyridyl)-3,4-dihydro-6-hydroxy-2,5,7,8-tetramethyl-2H-benzobilane having the following cicada properties was obtained. 4.0 g of -2-ylacetamide (compound 31)
Obtained. The yield and physical properties of the product are shown in Table 9.
実施例32〜46
°実施N3Jにおいて、N−(3−ピリジル)−6−ペ
ンジルオキソ−3,4−ジヒドロ−2,5,?、8−テ
トラメチルー2H−ベンゾピラン−2−イルアセトアミ
ドの代わりに実施例16〜3oにおいて合成した化合物
16〜30を用いた以外は同様にして反応及び分離操作
を行なうことにより、それぞれ対応するアミド化合物を
得た。生成物の収率及び物性値を第9表に示した。Examples 32-46 In Run N3J, N-(3-pyridyl)-6-penzyloxo-3,4-dihydro-2,5,? , 8-tetramethyl-2H-benzopyran-2-ylacetamide was replaced with Compounds 16 to 30 synthesized in Examples 16 to 3o, but the corresponding amide compounds were obtained by carrying out the reaction and separation operations in the same manner. Obtained. The yield and physical properties of the product are shown in Table 9.
以下余白
実施例47
〕cos
3−(6−アセトキシ−3,4−ジヒドロ−2,5,7
゜8−テトラメチル−2H−ベンゾピラン−2−イル)
アクリル酸4.3g (13,5gmol) 、塩化メ
チレン1001、塩化チオニル1.93g(16,2m
5ol)及びジメチルホルムアミド30μlの混合物を
室温で2時間加熱還流した。反応液を室温まで冷却した
後、低沸点物を減圧下に留去した。メチル 2−アミノ
ベンゾエート2.04g(13,5霞+1ol)と1.
2−ジクロロエタン100m1及びピリジン1.07g
(13,5■−ol)の混合溶液に水冷下で前述の方法
により合成した酸クロライドを滴下して、室温で終夜撹
拌した。反応液を水にあけてエーテルで抽出し、有機層
を無水硫酸ナトリウムで乾燥した後低沸点物を減圧下に
留去した。残渣をシリカゲルカラムクロマトグラフィー
にて精製することによりN−(2−メトキシカルボニル
フェニル)−2−(6−アセトキシ−3,4=ジヒドロ
−2,5,7,8−テトラメチル−211−ベンゾビラ
ン−2−イル)−アクリルアミド5.5gを得た。収率
9G、3%。Below is the margin Example 47] cos 3-(6-acetoxy-3,4-dihydro-2,5,7
゜8-tetramethyl-2H-benzopyran-2-yl)
Acrylic acid 4.3g (13.5gmol), methylene chloride 1001, thionyl chloride 1.93g (16.2m
A mixture of 5 ol) and 30 μl of dimethylformamide was heated under reflux at room temperature for 2 hours. After the reaction solution was cooled to room temperature, low-boiling substances were distilled off under reduced pressure. 2.04 g (13,5 haze + 1 ol) of methyl 2-aminobenzoate and 1.
100ml of 2-dichloroethane and 1.07g of pyridine
The acid chloride synthesized by the above method was added dropwise to a mixed solution of (13,5-ol) under water cooling, and the mixture was stirred at room temperature overnight. The reaction solution was poured into water and extracted with ether. The organic layer was dried over anhydrous sodium sulfate, and then low-boiling substances were distilled off under reduced pressure. The residue was purified by silica gel column chromatography to obtain N-(2-methoxycarbonylphenyl)-2-(6-acetoxy-3,4=dihydro-2,5,7,8-tetramethyl-211-benzobilane- 5.5 g of 2-yl)-acrylamide were obtained. Yield 9G, 3%.
水素化カリウム2.6g (46,4mmol)と水2
,61、エタノール15m1及びN−(2−メトキシカ
ルボニルフェニル)−2−(6−アセトキシ−3,4−
ジヒドロ−2,5,7,8−テトラメチル−2■−ベン
ゾビラン−2−イル)−アクリルアミド5.5g(12
,2+mmol)の混合溶液を3時間加熱還流した。反
応液を室温に冷却した後エタノールを除去して希塩酸で
酸性にし、エーテルで抽出した。有機層を無水硫酸ナト
リウムで乾燥した後低沸点物を減圧下に留去したのち残
渣をシリカゲルカラムクロマトグラフィーにて精製する
ことにより下記の物性を有するN−(2−カルボン酸フ
ェニル)−2−(3,4−ジヒドロ−6−ヒドロキシ−
2,5,7,8−テトラメチル−2H−ベンゾピラン−
2−イル)−アクリルアミド(化合物47)を4.35
9得た。収率90.3%・FDIx量スヘクトル:[M
]+=395実施例48
実施例15において3−アミノピリジン30smolの
代わりにメチル 2−アミノベンゾニー) 3G+sm
olを用いた以外は同様にして反応及び分離操作を行な
うことにより、対応するN−(2−メトキシカルボニル
フェニル)−3,4−ジヒドロ−6−ヒドロキシ−2,
4,7,8−テトラメチル−ベンゾビラン−2−イルア
セトアミドlO,5gを得た。収率86,5%。Potassium hydride 2.6g (46.4mmol) and water 2
,61, 15 ml of ethanol and N-(2-methoxycarbonylphenyl)-2-(6-acetoxy-3,4-
5.5 g (12
, 2+mmol) was heated under reflux for 3 hours. After the reaction solution was cooled to room temperature, ethanol was removed, acidified with dilute hydrochloric acid, and extracted with ether. After drying the organic layer over anhydrous sodium sulfate, low-boiling substances were distilled off under reduced pressure, and the residue was purified by silica gel column chromatography to obtain N-(2-carboxylic acid phenyl)-2- having the following physical properties. (3,4-dihydro-6-hydroxy-
2,5,7,8-tetramethyl-2H-benzopyran-
2-yl)-acrylamide (compound 47) at 4.35
I got 9. Yield: 90.3%・FDIx amount: [M
]+=395 Example 48 In Example 15, 30 smol of 3-aminopyridine was replaced with methyl 2-aminobenzony) 3G+sm
The corresponding N-(2-methoxycarbonylphenyl)-3,4-dihydro-6-hydroxy-2,
5 g of 4,7,8-tetramethyl-benzobilan-2-ylacetamide was obtained. Yield 86.5%.
実施例30においてIf−(3−ピリジル)−6ペンジ
ルオキシー3.4−ジヒドロ−2,5,7,8−テトラ
メチル−2H−ベンゾピラン−2−イルアセトアミド2
1.6ssolの代わりにN−(2−メトキシカルボニ
ルフェニル)−6−ベンジルオキシ−3,4−ジヒドロ
−2,4,7,8−テトラメチル−ベンゾピラン−2−
イルアセトアミド10.5g(21,6−sol)を用
いた以外は同様にして反応及び分離操作を行なうことに
よりN−(2−メトキシカルボニルフェニル)−3,4
−ジヒドロ−6−ヒドロキン−2,4゜7.8−テトラ
メチル−ベンゾピラン−2−イルアセトアミド6.5g
を得た。収率76.3%。If-(3-pyridyl)-6penzyloxy-3,4-dihydro-2,5,7,8-tetramethyl-2H-benzopyran-2-ylacetamide 2 in Example 30
N-(2-methoxycarbonylphenyl)-6-benzyloxy-3,4-dihydro-2,4,7,8-tetramethyl-benzopyran-2- instead of 1.6ssol
N-(2-methoxycarbonylphenyl)-3,4 was obtained by carrying out the reaction and separation procedure in the same manner except that 10.5 g (21,6-sol) of ylacetamide was used.
-dihydro-6-hydroquine-2,4゜7.8-tetramethyl-benzopyran-2-ylacetamide 6.5g
I got it. Yield 76.3%.
N−(2−メトキンカルボニルフェニル)−34−ジヒ
ドロ−6−ヒドロキシ−2,4,7,8−テトラメチル
−ベンゾピラン−2−イルアセトアミド6.5g (1
6,4snol)とエタノール301、水2ml及び水
酸化カリウム1.Ig (19,6m5ol)の混合溶
液を3時間加熱還流した。反応液を室温に冷却したのち
エタノールを除去して希塩酸で酸性にし、エーテルで抽
出した。有機層を無水硫酸ナトリウムで乾燥し、低沸点
物を減圧下に留去したのち残渣をノリカゲル力ラムクロ
マトグラフイーにて精製することにより下記の物性を有
するN−(2−カルボキシフェニル)−3,4−ジヒド
ロ−6−ヒドロキシ−2,5,7,8−テトラメチル−
ベンゾピラン−2イルアセトアミド(化合物48) 2
.6 gを得た。N-(2-methquinecarbonylphenyl)-34-dihydro-6-hydroxy-2,4,7,8-tetramethyl-benzopyran-2-ylacetamide 6.5 g (1
6,4 snol), 301 ml of ethanol, 2 ml of water, and 1. A mixed solution of Ig (19.6 m5 ol) was heated under reflux for 3 hours. After the reaction solution was cooled to room temperature, ethanol was removed, acidified with diluted hydrochloric acid, and extracted with ether. The organic layer was dried over anhydrous sodium sulfate, low-boiling substances were distilled off under reduced pressure, and the residue was purified by Norica gel column chromatography to obtain N-(2-carboxyphenyl)-3 having the following physical properties. ,4-dihydro-6-hydroxy-2,5,7,8-tetramethyl-
Benzopyran-2ylacetamide (compound 48) 2
.. 6 g was obtained.
収率16.4%。Yield 16.4%.
F D!fitスヘク) ル: [M]”=38:(実
施例49
実施例15において6−ベンジルオキシ−3,4−ジヒ
ドロ−2,5,7,8−テトラメチル−2■−ベンゾピ
ラン−2−イル酢酸及び3−アミノビ1ノジンの代わり
に6−ベンジルオキシ−3,4−ジヒドロ−2,5,7
,8−テトラメチル−2日−ベンゾピラン−2−イルプ
ロピオン酸25.0asol及びl−ジフェニルメチル
ビペラジン30.0員−01を用−)た以外(よ同様1
こして反応及び分離操作を行なうこと1こ上り下8己の
物性を有する6−ベンジルオキシ−2−(4−ジフェニ
ルメチルビペラジン−1−イル)カルボニルエチル−3
,4−ジヒドロ−2,5,7,8−テトラメチル−2H
−ベンゾピラン(化合物49)を5,309得た。収率
35,2%。FD! [M]”=38: (Example 49 In Example 15, 6-benzyloxy-3,4-dihydro-2,5,7,8-tetramethyl-2■-benzopyran-2-yl 6-benzyloxy-3,4-dihydro-2,5,7 instead of acetic acid and 3-aminobi-1-nodine
, 8-tetramethyl-2-benzopyran-2-ylpropionic acid (25.0 asol) and l-diphenylmethylbiperazine (30.0-01) (as in 1).
6-benzyloxy-2-(4-diphenylmethylbiperazin-1-yl)carbonylethyl-3 having the following physical properties is then subjected to reaction and separation operations.
,4-dihydro-2,5,7,8-tetramethyl-2H
5,309 of -benzopyran (compound 49) was obtained. Yield 35.2%.
FD質量スペクトル: [M]”= 802’H−N
M Rスペクトル(CDCl5) : δ1.32(s
、3B)。FD mass spectrum: [M]"=802'H-N
MR spectrum (CDCl5): δ1.32(s
, 3B).
1.81〜1.95(s、2H)、 1.96.2.
05,2.12(3g、91)。1.81-1.95 (s, 2H), 1.96.2.
05, 2.12 (3g, 91).
2.20〜2.36(a、4H)、2.45〜2.57
(+、4)1)、2.56(s、2H)、3.29〜3
.65(m、4tl)、4.12(s、211)4.2
0(s、IH)、 7.005−7J9(,15H)
実施例5O
N−(3−ピリジル)−6−ペンノルオキシ3.4−ジ
ヒドロ−2,5,7,8−テトラメチル−2Hベンゾビ
ラン−2−イルアセトアミドの代わりに実施例49にお
いて合成した6−ペンノルオキシー2−(4−ジフェニ
ルメチルビペラジン−1−イル)カルボニルエチル−3
,4−ジヒドロ−2,5,7,8−テトラメチル−2H
−ベンゾピランを用いた以外は同様にして反応及び分離
操作を行なうことにより下記の物性を有する2−(4−
ジフェニルメチルビペラジン−1−イル)カルボニルエ
チル−3,4−ジヒドロ−6−ヒドロキシ−2,5,7
,8−テトラメチル−2H−ベンゾピラン(化合物50
)を得た。2.20-2.36 (a, 4H), 2.45-2.57
(+, 4) 1), 2.56 (s, 2H), 3.29-3
.. 65 (m, 4tl), 4.12 (s, 211) 4.2
0(s, IH), 7.005-7J9(,15H)
Example 5O 6-pene synthesized in Example 49 in place of N-(3-pyridyl)-6-pennoloxy 3,4-dihydro-2,5,7,8-tetramethyl-2H benzobylan-2-ylacetamide Noroxy-2-(4-diphenylmethylbiperazin-1-yl)carbonylethyl-3
,4-dihydro-2,5,7,8-tetramethyl-2H
-2-(4-
diphenylmethylbiperazin-1-yl)carbonylethyl-3,4-dihydro-6-hydroxy-2,5,7
, 8-tetramethyl-2H-benzopyran (compound 50
) was obtained.
収率46,5%。Yield 46.5%.
FDji量スペクトル: [M]”= 512H−NM
Rスペクトル(CDC1i) : δ1.31(s、3
H)。FDji quantity spectrum: [M]”= 512H-NM
R spectrum (CDC1i): δ1.31(s, 3
H).
1.80〜1.96(t1、2H)、 1.9?、2
.04,2.11C3s、9H)。1.80-1.96 (t1, 2H), 1.9? ,2
.. 04, 2.11C3s, 9H).
2.20〜2.33(m、48)、 2.46〜2.
57(s、4H)、 2.56(s、2H)、 3
.27〜3.67(m、4H)、 4.15(s、I
H)。2.20-2.33 (m, 48), 2.46-2.
57 (s, 4H), 2.56 (s, 2H), 3
.. 27-3.67 (m, 4H), 4.15 (s, I
H).
700〜7.35(m、l0H)
(発明の効果)
本発明によれば、医薬として有用な新規な3.4〜ジヒ
ドロ−2H−ベンゾピラン誘導体(1−1)及び該誘導
体の合成中間体として有用な新規な3,4ジヒドロ−2
H−ベンゾピラン誘導体(1−2)が提供される。3.
4−ジヒドロ−2H−ベンゾピラン誘導体(+1)は、
前記の試験の結果から明らかなとおり、5−リボキンゲ
ナーゼ阻害作用とともに抗ヒスタミン作用を併せ持ち、
しかも安全性が高く、抗アレルギー剤として有用である
。また、3,4ジヒドロ−2日−ベンゾピラン誘導体(
I−1)は、脂質過酸化防止作用及び鎮痛作用を有する
ので、各種虚血性疾患治療剤及び鎮痛剤としても期待さ
れる。700-7.35 (m, 10H) (Effects of the Invention) According to the present invention, a novel 3.4-dihydro-2H-benzopyran derivative (1-1) useful as a pharmaceutical and a synthetic intermediate for the derivative Useful new 3,4 dihydro-2
H-benzopyran derivatives (1-2) are provided. 3.
4-dihydro-2H-benzopyran derivative (+1) is
As is clear from the results of the above test, it has both 5-riboquine genease inhibitory action and antihistamine action,
Moreover, it is highly safe and useful as an antiallergic agent. In addition, 3,4 dihydro-2-day-benzopyran derivative (
Since I-1) has anti-lipid peroxidation and analgesic effects, it is expected to be used as a therapeutic agent for various ischemic diseases and as an analgesic.
Claims (1)
、R^2は水素原子、置換基を有していてもよい直鎖ア
ルキル基、置換基を有していてもよいアリール基若しく
はピリジル基を表わすか、又はR^1とR^2が一緒に
なつて式−(CH_2)_2O(CH_2)_2−で示
される基、式−(CH_2)_2S(CH_2)_2−
で示される基、式▲数式、化学式、表等があります▼で
示される基若しくは 式▲数式、化学式、表等があります▼で示される基を表
わし、R^3は水素原子又は水酸基の保護基を表わし、
R^4は水素原子、置換基を有していてもよいアリール
基又は置換基を有していてもよいアラルキル基を表わし
、nは0、1又は2の整数を表わし、mは0又は1の整
数を表わす) で示される3,4−ジヒドロ−2H−ベンゾピラン誘導
体。 2、請求項1において、R^3が水素原子である請求項
1記載の3,4−ジヒドロ−1−ベンゾピラン誘導体。 3、治療上有効な量の請求項2記載の化合物の少なくと
も1種と医薬上許容される添加剤とからなる医薬組成物
。 4、医薬用途が5−リポキシゲナーゼ作用、ヒスタミン
作用、発痛作用及び脂質過酸化作用のうちの少なくとも
一種に起因する疾病の治療用である請求項3記載の医薬
組成物。 5、医薬用途が気管支喘息、アレルギー性疾患、免疫性
疾患、乾癬、脳血管障害、虚血性心疾患、疼痛及び血栓
症から選ばれる少なくとも一種の治療用である請求項3
記載の医薬組成物。[Claims] 1. General formula ▲ Numerical formula, chemical formula, table, etc. ▼ (In the formula, R^1 represents a hydrogen atom or a lower alkyl group, and R^2 has a hydrogen atom or a substituent. represents a straight chain alkyl group which may optionally have a substituent, an aryl group which may have a substituent, or a pyridyl group, or R^1 and R^2 taken together form the formula -(CH_2)_2O(CH_2)_2- A group represented by the formula -(CH_2)_2S(CH_2)_2-
Represents a group or group represented by the formula ▲There are mathematical formulas, chemical formulas, tables, etc.▼ or a group represented by the formula ▲There are mathematical formulas, chemical formulas, tables, etc.▼, and R^3 is a hydrogen atom or a group that protects a hydroxyl group. represents,
R^4 represents a hydrogen atom, an aryl group which may have a substituent, or an aralkyl group which may have a substituent, n represents an integer of 0, 1 or 2, and m is 0 or 1. 3,4-dihydro-2H-benzopyran derivative represented by (representing an integer of ). 2. The 3,4-dihydro-1-benzopyran derivative according to claim 1, wherein R^3 is a hydrogen atom. 3. A pharmaceutical composition comprising a therapeutically effective amount of at least one compound according to claim 2 and a pharmaceutically acceptable additive. 4. The pharmaceutical composition according to claim 3, which is used for the treatment of diseases caused by at least one of the following: 5-lipoxygenase action, histamine action, pain-causing action, and lipid peroxidation action. 5. Claim 3, wherein the medical use is for the treatment of at least one selected from bronchial asthma, allergic diseases, immune diseases, psoriasis, cerebrovascular disorders, ischemic heart diseases, pain, and thrombosis.
Pharmaceutical compositions as described.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP3570389A JPH02215778A (en) | 1989-02-14 | 1989-02-14 | 3,4-dihydro-2h-benzopyrane derivative and medical use of the same compound |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP3570389A JPH02215778A (en) | 1989-02-14 | 1989-02-14 | 3,4-dihydro-2h-benzopyrane derivative and medical use of the same compound |
Publications (1)
Publication Number | Publication Date |
---|---|
JPH02215778A true JPH02215778A (en) | 1990-08-28 |
Family
ID=12449233
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP3570389A Pending JPH02215778A (en) | 1989-02-14 | 1989-02-14 | 3,4-dihydro-2h-benzopyrane derivative and medical use of the same compound |
Country Status (1)
Country | Link |
---|---|
JP (1) | JPH02215778A (en) |
Cited By (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH06172339A (en) * | 1991-05-03 | 1994-06-21 | Adir | New benzopyran compound, its production and medicinal composition containing it |
EP0604995A1 (en) * | 1992-12-31 | 1994-07-06 | LIFEGROUP S.p.A. | Hydroxyamines N-acyl derivatives having scavenger activity and useful in acute and chronic pathologies associated with peroxidation and inflammation phenomena |
JPH06192248A (en) * | 1992-09-09 | 1994-07-12 | Adir | New benzopyran, its production and pharmaceutical composition containing same |
FR2733685A1 (en) * | 1995-05-05 | 1996-11-08 | Adir | USE OF BENZOPYRANE DERIVATIVES FOR THE PRODUCTION OF PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OF CONDITIONS RELATED TO THE C1- / HC03-, NA + INDEPENDENT EXCHANGER |
US5747528A (en) * | 1996-02-21 | 1998-05-05 | Warner-Lambert Company | Chroman derivatives as anti-oxidants |
JP2004504268A (en) * | 2000-02-11 | 2004-02-12 | リサーチ ディベロップメント ファンデーション | Tocopherols, tocotrienols, other chromans, and their side-chain derivatives and their uses |
WO2005016867A3 (en) * | 2003-08-14 | 2005-03-31 | Smithkline Beecham Corp | Anthranilic acid derivatives and their use as activators of the hm74a receptor |
-
1989
- 1989-02-14 JP JP3570389A patent/JPH02215778A/en active Pending
Cited By (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH06172339A (en) * | 1991-05-03 | 1994-06-21 | Adir | New benzopyran compound, its production and medicinal composition containing it |
JPH06192248A (en) * | 1992-09-09 | 1994-07-12 | Adir | New benzopyran, its production and pharmaceutical composition containing same |
EP0604995A1 (en) * | 1992-12-31 | 1994-07-06 | LIFEGROUP S.p.A. | Hydroxyamines N-acyl derivatives having scavenger activity and useful in acute and chronic pathologies associated with peroxidation and inflammation phenomena |
US5480645A (en) * | 1992-12-31 | 1996-01-02 | Lifegroup S.P.A. | Hydroxyamines N-acyl derivatives having scavenger activity and useful in acute and chronic pathologies associated with peroxidation and inflammation phenomena |
FR2733685A1 (en) * | 1995-05-05 | 1996-11-08 | Adir | USE OF BENZOPYRANE DERIVATIVES FOR THE PRODUCTION OF PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OF CONDITIONS RELATED TO THE C1- / HC03-, NA + INDEPENDENT EXCHANGER |
EP0740936A3 (en) * | 1995-05-05 | 1997-01-15 | Adir | Use of benzopyran derivatives for the manufacture of medicaments for the treatment of diseases connected with the sodium independent Cl-/HCO3- exchanger |
US5747528A (en) * | 1996-02-21 | 1998-05-05 | Warner-Lambert Company | Chroman derivatives as anti-oxidants |
JP2004504268A (en) * | 2000-02-11 | 2004-02-12 | リサーチ ディベロップメント ファンデーション | Tocopherols, tocotrienols, other chromans, and their side-chain derivatives and their uses |
WO2005016867A3 (en) * | 2003-08-14 | 2005-03-31 | Smithkline Beecham Corp | Anthranilic acid derivatives and their use as activators of the hm74a receptor |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US5958950A (en) | Benzimidazole compounds useful for the treatment of inflammatory disease, atherosclerosis, restenosis or inhibiting lipoxygenase | |
JPH05508845A (en) | Substituted bicyclic bis-aryl compositions exhibiting selective leukotriene B4 antagonistic activity, their preparation and use in pharmaceutical compositions | |
JPH11504947A (en) | N-Aminoalkyldibenzofurancarboxamides as dopamine receptor subtype specific ligands | |
AU611827B2 (en) | Imidazoline derivative and preparation thereof | |
JPH08169884A (en) | Cyclopropachromenecarboxylic acid derivative | |
KR20150070348A (en) | Heteroaryl linked quinolinyl modulators of rorγt | |
JP2022533740A (en) | Disubstituted sulfamide-based selective BCL-2 inhibitors containing methyl and trifluoromethyl groups | |
JP2001512727A (en) | Bicyclic compounds as ligands for the 5HT-1 receptor | |
WO2014127722A1 (en) | Dihydroartemisinin substituted by nitrogen containing heterocycle derivative and use thereof | |
KR900006118B1 (en) | Process for preparing 4-quinolone derivatives | |
JPH02215778A (en) | 3,4-dihydro-2h-benzopyrane derivative and medical use of the same compound | |
US4243666A (en) | 4-Amino-2-piperidino-quinazolines | |
JPH037257A (en) | Pyridine derivative and psychotropic agent containing the derivative as active ingredient | |
KR100538152B1 (en) | Diamine derivatives and pharmaceutical containing the same | |
WO1987005020A1 (en) | 3,4-dihydro-2h-benzopyran derivatives and their medicinal use | |
US4988699A (en) | Substituted tetrahydrobenzothiazoles as dopaminergic agents | |
CN112771025A (en) | Deuterated compounds as ROCK inhibitors | |
WO1998058930A1 (en) | Triazolo-1,4-diazepine compounds and medicinal composition containing the same | |
JPH10316570A (en) | Tnf-alpha inductive effect inhibitor | |
RU2179556C2 (en) | DERIVATIVES OF 7-[3-[4-(6-FLUOROBENZO[D]ISOXAZOL-3-YL)-PIPERIDINE-1-YL]PROPOXY]- CHROMEN-4-ONE, METHOD OF THEIR SYNTHESIS, PHARMACEUTICAL COMPOSITION FOR INHIBITION OF D2-, 5-HT2a- AND H1-RECEPTORS AND METHOD OF INHIBITION OF D2-, 5-HT2a- AND H1-RECEPTORS IN TREATMENT OF PSYCHOSIS AND SCHIZOPHRENIA | |
US6025493A (en) | N-piperazinylalkyl-2-anthracenecarboxamides | |
US5952326A (en) | Tetralin and chroman derivatives useful in the treatment of asthma, arthritis and related diseases | |
IE912491A1 (en) | 1,4-disubstituted piperazines | |
US5698550A (en) | Tetralin and chroman derivatives useful in the treatment of asthma, arthritis and related diseases | |
EP0441515B1 (en) | Tetralin and chroman derivatives in the treatment of asthma, arthritis and related diseases |